

**Contact**

Merck KGaA, Darmstadt, Germany  
Investor Relations  
Frankfurter Strasse 250  
64293 Darmstadt  
Germany  
Phone: +49 6151 72 3321  
e-mail: investor.relations@merckgroup.com  
www.merckgroup.com

WKN: 659990  
ISIN: DE0006599905  
Ticker Symbol: MRK

# Financial Statements Q1 2023 – Q1 2024

**Content**

---

**1 Income statements**

- 1.1 Group, quarterly
- 1.2 Life Science, quarterly
- 1.3 Healthcare, quarterly
- 1.4 Electronics, quarterly
- 1.5 Corporate/Others, quarterly
- 1.6 Financial result, quarterly

**2 Cash flow statement****3 Balance sheet**



Income Statement Merck KGaA, Darmstadt, Germany

| Group<br>€ million   | 2023           |                |                 |                |                 |                |                 |                 | 2024           |    |    |    |    |    |    |    | Change YoY |    |    |    |    |    |    |    |  |       |        |        |
|--|----------------|----------------|-----------------|----------------|-----------------|----------------|-----------------|-----------------|----------------|----|----|----|----|----|----|----|------------|----|----|----|----|----|----|----|--|-------|--------|--------|
|  | Q1             | Q2             | H1              | Q3             | 9M              | Q4             | H2              | FY              | Q1             | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1         | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |  |       |        |        |
| <b>Net sales</b>   | <b>5,293.0</b> | <b>5,302.4</b> | <b>10,595.3</b> | <b>5,173.1</b> | <b>15,768.4</b> | <b>5,224.5</b> | <b>10,397.6</b> | <b>20,992.9</b> | <b>5,119.8</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -3.3% |        |        |
| Cost of sales  | -1,972.5       | -2,138.9       | -4,111.4        | -2,161.8       | -6,273.2        | -2,327.3       | -4,489.1        | -8,600.5        | -2,110.6       |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | 7.0%   |        |
| thereof amortization of intangible assets  | -48.2          | -46.2          | -94.3           | -40.3          | -134.7          | -38.6          | -78.9           | -173.2          | -38.2          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -20.6% |        |
| Gross profit   | 3,320.4        | 3,163.5        | 6,483.9         | 3,011.3        | 9,495.2         | 2,897.2        | 5,908.5         | 12,392.4        | 3,009.2        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -9.4%  |        |
| <i>in % of net sales</i>   | 62.7%          | 59.7%          | 61.2%           | 58.2%          | 60.2%           | 55.5%          | 56.8%           | 59.0%           | 58.8%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       |        |        |
| SG&A   | -1,688.2       | -1,593.6       | -3,281.8        | -1,447.0       | -4,728.8        | -1,609.3       | -3,056.3        | -6,338.1        | -1,497.3       |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -11.3% |        |
| <i>in % of net sales</i>   | 31.9%          | 30.1%          | 31.0%           | 28.0%          | 30.0%           | 30.8%          | 29.4%           | 30.2%           | 29.2%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       |        |        |
| Marketing and selling expenses   | -1,109.1       | -1,139.4       | -2,248.5        | -1,104.3       | -3,352.9        | -1,157.5       | -2,261.8        | -4,510.4        | -1,087.1       |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -2.0%  |        |
| thereof amortization of intangible assets (M&S)  | -151.3         | -148.9         | -300.2          | -146.7         | -446.9          | -149.3         | -296.0          | -596.2          | -144.7         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -4.3%  |        |
| Administration expenses  | -357.9         | -345.0         | -702.9          | -312.0         | -1,014.9        | -377.4         | -689.4          | -1,392.3        | -331.7         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -7.3%  |        |
| Impairment losses and reversals (IFRS 9)   | -2.2           | -9.7           | -11.9           | -28.3          | -40.2           | -10.3          | -38.6           | -50.5           | 1.0            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | n.m.   |        |
| Other operating expenses/income  | -219.0         | -99.4          | -318.4          | -2.3           | -320.8          | -64.1          | -66.5           | -384.9          | -79.5          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -63.7% |        |
| Impairments**  | -9.7           | -36.9          | -46.6           | -3.8           | -50.4           | -36.9          | -40.7           | -87.2           | -0.5           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -95.1% |        |
| Research and development costs   | -597.3         | -600.4         | -1,197.7        | -581.1         | -1,778.8        | -666.5         | -1,247.5        | -2,445.2        | -580.6         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -2.8%  |        |
| <i>in % of net sales</i>   | 11.3%          | 11.3%          | 11.3%           | 11.2%          | 11.3%           | 12.8%          | 12.0%           | 11.6%           | 11.3%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       |        |        |
| thereof amortization of intangible assets (R&D)  | -4.4           | -3.0           | -7.4            | -3.2           | -10.6           | -3.4           | -6.5            | -14.0           | -3.3           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -25.6% |        |
| <b>EBIT</b>  | <b>1,035.0</b> | <b>969.5</b>   | <b>2,004.4</b>  | <b>983.2</b>   | <b>2,987.7</b>  | <b>621.5</b>   | <b>1,604.7</b>  | <b>3,609.1</b>  | <b>931.3</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -10.0% |        |
| <i>in % of net sales</i>   | 19.6%          | 18.3%          | 18.9%           | 19.0%          | 18.9%           | 11.9%          | 15.4%           | 17.2%           | 18.2%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       |        |        |
| Depreciation and amortization  | 455.5          | 482.3          | 937.8           | 435.2          | 1,373.0         | 506.7          | 941.9           | 1,879.7         | 453.5          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -0.4%  |        |
| <b>EBITDA</b>  | <b>1,490.5</b> | <b>1,451.8</b> | <b>2,942.3</b>  | <b>1,418.4</b> | <b>4,360.7</b>  | <b>1,128.2</b> | <b>2,546.6</b>  | <b>5,488.9</b>  | <b>1,384.8</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -7.1%  |        |
| <i>in % of net sales</i>   | 28.2%          | 27.4%          | 27.8%           | 27.4%          | 27.7%           | 21.6%          | 24.5%           | 26.1%           | 27.0%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       |        |        |
| <b>EBITDA pre</b>  | <b>1,587.0</b> | <b>1,553.3</b> | <b>3,140.3</b>  | <b>1,445.6</b> | <b>4,585.9</b>  | <b>1,293.0</b> | <b>2,738.7</b>  | <b>5,878.9</b>  | <b>1,453.9</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -8.4%  |        |
| <i>in % of net sales</i>   | 30.0%          | 29.3%          | 29.6%           | 27.9%          | 29.1%           | 24.7%          | 26.3%           | 28.0%           | 28.4%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       |        |        |
| Financial result   | -22.7          | -75.7          | -98.4           | -46.0          | -144.3          | 19.1           | -26.8           | -125.2          | -32.2          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | 42.1%  |        |
| Profit before income tax from continuing operations  | 1,012.3        | 893.8          | 1,906.1         | 937.3          | 2,843.3         | 640.6          | 1,577.9         | 3,483.9         | 899.1          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -11.2% |        |
| Income tax   | -212.6         | -187.7         | -400.3          | -196.8         | -597.1          | -53.0          | -249.8          | -650.1          | -199.6         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -6.1%  |        |
| <i>Income tax rate</i>   | 21.0%          | 21.0%          | 21.0%           | 21.0%          | 21.0%           | 8.3%           | 15.8%           | 18.7%           | 22.2%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       |        |        |
| Profit after tax from continuing operations  | 799.7          | 706.1          | 1,505.8         | 740.4          | 2,246.2         | 587.6          | 1,328.0         | 2,833.8         | 699.5          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -12.5% |        |
| Profit after tax from discontinued operations  | 0.0            | 0.0            | 0.0             | 0.0            | 0.0             | 0.0            | 0.0             | 0.0             | 0.0            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | n.m.   |        |
| Profit after tax   | 799.7          | 706.1          | 1,505.8         | 740.4          | 2,246.2         | 587.6          | 1,328.0         | 2,833.8         | 699.5          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -12.5% |        |
| <b>of which: attributable to Merck KGaA shareholders (n of which: attributable to non-controlling interests)</b> | <b>796.2</b>   | <b>703.6</b>   | <b>1,499.8</b>  | <b>738.7</b>   | <b>2,238.4</b>  | <b>585.3</b>   | <b>1,323.9</b>  | <b>2,823.7</b>  | <b>694.2</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -12.8% |        |
|  | <b>3.5</b>     | <b>2.5</b>     | <b>6.0</b>      | <b>1.8</b>     | <b>7.8</b>      | <b>2.3</b>     | <b>4.1</b>      | <b>10.1</b>     | <b>5.2</b>     |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | 48.4%  |        |
| <b>EPS in €</b>  | <b>1.83</b>    | <b>1.62</b>    | <b>3.45</b>     | <b>1.70</b>    | <b>5.15</b>     | <b>1.35</b>    | <b>3.05</b>     | <b>6.49</b>     | <b>1.60</b>    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -12.6% |        |
| thereof from continuing operations   | 1.83           | 1.62           | 3.45            | 1.70           | 5.15            | 1.35           | 3.05            | 6.49            | 1.60           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       |        | -12.6% |
| thereof from discontinued operations   | 0.00           | 0.00           | 0.00            | 0.00           | 0.00            | 0.00           | 0.00            | 0.00            | 0.00           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | n.m.   |        |
| <b>EPS pre in €* </b>  | <b>2.36</b>    | <b>2.20</b>    | <b>4.57</b>     | <b>2.07</b>    | <b>6.64</b>     | <b>1.85</b>    | <b>3.92</b>     | <b>8.49</b>     | <b>2.06</b>    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -12.7% |        |
| <b>Number of theoretical shares in million</b>   | <b>434.8</b>   | <b>434.8</b>   | <b>434.8</b>    | <b>434.8</b>   | <b>434.8</b>    | <b>434.8</b>   | <b>434.8</b>    | <b>434.8</b>    | <b>434.8</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       |        |        |
| <b>Reconciliation to EBITDA pre</b>  |                |                |                 |                |                 |                |                 |                 |                |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       |        |        |
| EBITDA   | 1,490.5        | 1,451.8        | 2,942.3         | 1,418.4        | 4,360.7         | 1,128.2        | 2,546.6         | 5,488.9         | 1,384.8        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -7.1%  |        |
| <b>Adjustments</b>   |                |                |                 |                |                 |                |                 |                 |                |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       |        |        |
| thereof: Cost of Sales   | 2.7            | 4.6            | 7.2             | 10.4           | 17.6            | 24.9           | 35.3            | 42.6            | 4.1            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | 53.8%  |        |
| thereof: Marketing and selling expenses  | -0.9           | 5.4            | 4.5             | 8.0            | 12.4            | 31.9           | 39.9            | 44.3            | 9.1            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | n.m.   |        |
| thereof: Administration expenses   | 71.7           | 41.9           | 113.6           | 33.9           | 147.5           | 98.3           | 132.2           | 245.8           | 43.0           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -40.0% |        |
| thereof: Other operating expenses/income   | 30.9           | 42.1           | 73.0            | -25.5          | 47.5            | 2.9            | -22.6           | 50.5            | 7.5            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -75.7% |        |
| thereof: Research and development  | -7.9           | 7.6            | -0.3            | 0.5            | 0.1             | 6.8            | 7.2             | 6.9             | 5.4            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | n.m.   |        |
| <b>Total</b>   | <b>96.5</b>    | <b>101.5</b>   | <b>198.0</b>    | <b>27.2</b>    | <b>225.2</b>    | <b>164.9</b>   | <b>192.1</b>    | <b>390.1</b>    | <b>69.1</b>    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -28.4% |        |
| <b>EBITDA pre</b>  | <b>1,587.0</b> | <b>1,553.3</b> | <b>3,140.3</b>  | <b>1,445.6</b> | <b>4,585.9</b>  | <b>1,293.0</b> | <b>2,738.7</b>  | <b>5,878.9</b>  | <b>1,453.9</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |       | -8.4%  |        |

Due to rounding the sum of individual values may not add up to totals presented.

\* For continuing operations.

\*\* Only reflects impairments classified as adjustments.

**Reconciliation to EBITDA, EBITDA pre and EPS pre**

| Group<br>€ million                                       | 2023           |                |                |                |                |                |                |                | 2024           |    |    |    |    |    |    |    | Change YoY |    |    |    |    |    |    |    |  |         |
|--|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----|----|----|----|----|----|----|------------|----|----|----|----|----|----|----|--|---------|
|  | Q1             | Q2             | H1             | Q3             | 9M             | Q4             | H2             | FY             | Q1             | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1         | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |  |         |
| <b>a) Reconciliation to EBITDA and EBITDA pre</b>        |                |                |                |                |                |                |                |                |                |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |
| <b>EBITDA</b>  |                |                |                |                |                |                |                |                |                |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |
| EBIT   | 1,035.0        | 969.5          | 2,004.4        | 983.2          | 2,987.7        | 621.5          | 1,604.7        | 3,609.1        | 931.3          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -10.0%  |
| Depreciation and amortization                            | 455.5          | 482.3          | 937.8          | 435.2          | 1,373.0        | 506.7          | 941.9          | 1,879.7        | 453.5          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -0.4%   |
| Regular depreciation and amortization*                   | 242.0          | 243.2          | 485.2          | 241.1          | 726.3          | 266.9          | 508.0          | 993.2          | 257.6          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 6.5%    |
| Impairments not adjusted                                 | 0.0            | 4.2            | 4.2            | 0.0            | 4.2            | 11.8           | 11.8           | 16.0           | 9.2            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | >1.000% |
| Amortization of purchased intangible assets              | 203.8          | 198.1          | 401.9          | 190.3          | 592.2          | 191.2          | 381.5          | 783.3          | 186.2          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -8.6%   |
| Impairments (net)**                                      | 9.7            | 36.9           | 46.6           | 3.8            | 50.4           | 36.9           | 40.7           | 87.2           | 0.5            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -95.1%  |
| <b>Total</b>   | <b>1,490.5</b> | <b>1,451.8</b> | <b>2,942.3</b> | <b>1,418.4</b> | <b>4,360.7</b> | <b>1,128.2</b> | <b>2,546.6</b> | <b>5,488.9</b> | <b>1,384.8</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -7.1%   |
| <b>Adjustments</b>                                       |                |                |                |                |                |                |                |                |                |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |
| Acquisition costs  | 9.2            | 4.8            | 14.0           | 3.7            | 17.7           | 0.8            | 4.4            | 18.5           | 2.5            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -72.7%  |
| Restructuring costs                                      | 44.3           | 39.3           | 83.6           | 24.6           | 108.2          | 140.3          | 164.9          | 248.5          | 44.6           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 0.7%    |
| Integration costs/IT costs                               | 23.5           | 27.1           | 50.6           | 28.8           | 79.4           | 39.0           | 67.8           | 118.4          | 17.4           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -26.1%  |
| Gain (-)/ losses (+) on the divestment of businesses     | 0.3            | 17.1           | 17.4           | -48.8          | -31.4          | -20.1          | -68.8          | -51.4          | -4.8           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | n.m.    |
| Other one-time costs                                     | 19.2           | 13.2           | 32.4           | 18.9           | 51.3           | 4.8            | 23.7           | 56.1           | 9.4            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -51.2%  |
| <b>Total</b>   | <b>96.5</b>    | <b>101.5</b>   | <b>198.0</b>   | <b>27.2</b>    | <b>225.2</b>   | <b>164.9</b>   | <b>192.1</b>   | <b>390.1</b>   | <b>69.1</b>    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -28.4%  |
| <b>EBITDA pre</b>  | <b>1,587.0</b> | <b>1,553.3</b> | <b>3,140.3</b> | <b>1,445.6</b> | <b>4,585.9</b> | <b>1,293.0</b> | <b>2,738.7</b> | <b>5,878.9</b> | <b>1,453.9</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -8.4%   |
| <b>b) Reconciliation to EPS pre</b>                      |                |                |                |                |                |                |                |                |                |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |
| <b>1) Reconciliation starting from EBITDA pre</b>        |                |                |                |                |                |                |                |                |                |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |
| EBITDA pre   | 1,587.0        | 1,553.3        | 3,140.3        | 1,445.6        | 4,585.9        | 1,293.0        | 2,738.7        | 5,878.9        | 1,453.9        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -8.4%   |
| Regular depreciation and amortization*                   | -242.0         | -243.2         | -485.2         | -241.1         | -726.3         | -266.9         | -508.0         | -993.2         | -257.6         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 6.5%    |
| Impairments not adjusted                                 | 0.0            | -4.2           | -4.2           | 0.0            | -4.2           | -11.8          | -11.8          | -16.0          | -9.2           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | >1.000% |
| Financial result   | -22.7          | -75.7          | -98.4          | -46.0          | -144.3         | 19.1           | -26.8          | -125.2         | -32.2          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 42.1%   |
| Adjustments within Financial result                      | 0.0            | 0.0            | 0.0            | 0.0            | 0.0            | 0.0            | 0.0            | 0.0            | 0.0            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |
| Profit before income tax pre                             | 1,322.3        | 1,230.2        | 2,552.5        | 1,158.5        | 3,711.1        | 1,033.5        | 2,192.1        | 4,744.6        | 1,154.8        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -12.7%  |
| Income tax pre   | -290.9         | -270.6         | -561.6         | -254.9         | -816.4         | -227.4         | -482.3         | -1,043.8       | -254.1         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -12.7%  |
| underlying tax rate                                      | 22.0%          | 22.0%          | 22.0%          | 22.0%          | 22.0%          | 22.0%          | 22.0%          | 22.0%          | 22.0%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |
| Non-controlling interest                                 | -3.5           | -2.5           | -6.0           | -1.8           | -7.8           | -2.3           | -4.1           | -10.1          | -5.2           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 48.4%   |
| Net income pre   | 1,027.9        | 957.1          | 1,984.9        | 901.9          | 2,886.8        | 803.9          | 1,705.7        | 3,690.7        | 895.6          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -12.9%  |
| <b>EPS pre in €***</b>                                   | <b>2.36</b>    | <b>2.20</b>    | <b>4.57</b>    | <b>2.07</b>    | <b>6.64</b>    | <b>1.85</b>    | <b>3.92</b>    | <b>8.49</b>    | <b>2.06</b>    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -12.7%  |
| <b>2) Reconciliation starting from Profit before tax</b> |                |                |                |                |                |                |                |                |                |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |
| Profit before income tax                                 | 1,012.3        | 893.8          | 1,906.1        | 937.3          | 2,843.3        | 640.6          | 1,577.9        | 3,483.9        | 899.1          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -11.2%  |
| Amortization of purchased intangible assets              | 203.8          | 198.1          | 401.9          | 190.3          | 592.2          | 191.2          | 381.5          | 783.3          | 186.2          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -8.6%   |
| Impairments**  | 9.7            | 36.9           | 46.6           | 3.8            | 50.4           | 36.9           | 40.7           | 87.2           | 0.5            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -95.1%  |
| <b>Adjustments</b>                                       |                |                |                |                |                |                |                |                |                |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |
| Acquisition costs  | 9.2            | 4.8            | 14.0           | 3.7            | 17.7           | 0.8            | 4.4            | 18.5           | 2.5            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -72.7%  |
| Restructuring costs                                      | 44.3           | 39.3           | 83.6           | 24.6           | 108.2          | 140.3          | 164.9          | 248.5          | 44.6           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 0.7%    |
| Integration costs/IT costs                               | 23.5           | 27.1           | 50.6           | 28.8           | 79.4           | 39.0           | 67.8           | 118.4          | 17.4           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -26.1%  |
| Gain (-)/ losses (+) on the divestment of businesses     | 0.3            | 17.1           | 17.4           | -48.8          | -31.4          | -20.1          | -68.8          | -51.4          | -4.8           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | n.m.    |
| Other one-time costs                                     | 19.2           | 13.2           | 32.4           | 18.9           | 51.3           | 4.8            | 23.7           | 56.1           | 9.4            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -51.2%  |
| Adjustments within Financial result                      | 0.0            | 0.0            | 0.0            | 0.0            | 0.0            | 0.0            | 0.0            | 0.0            | 0.0            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |
| Total adjustments  | 96.5           | 101.5          | 198.0          | 27.2           | 225.2          | 164.9          | 192.1          | 390.1          | 69.1           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -28.4%  |
| Profit before income tax pre                             | 1,322.3        | 1,230.2        | 2,552.5        | 1,158.5        | 3,711.1        | 1,033.5        | 2,192.1        | 4,744.6        | 1,154.8        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -12.7%  |
| Income tax pre   | -290.9         | -270.6         | -561.6         | -254.9         | -816.4         | -227.4         | -482.3         | -1,043.8       | -254.1         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -12.7%  |
| underlying tax rate                                      | 22.0%          | 22.0%          | 22.0%          | 22.0%          | 22.0%          | 22.0%          | 22.0%          | 22.0%          | 22.0%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |
| <b>Total costs excluded from Net income</b>              | <b>231.7</b>   | <b>253.5</b>   | <b>485.2</b>   | <b>163.2</b>   | <b>648.4</b>   | <b>218.6</b>   | <b>381.8</b>   | <b>867.0</b>   | <b>201.3</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -13.1%  |
| <b>Total costs excluded from EPS in €</b>                | <b>0.53</b>    | <b>0.58</b>    | <b>1.12</b>    | <b>0.38</b>    | <b>1.49</b>    | <b>0.50</b>    | <b>0.88</b>    | <b>1.99</b>    | <b>0.46</b>    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -13.2%  |
| Non-controlling interest                                 | -3.5           | -2.5           | -6.0           | -1.8           | -7.8           | -2.3           | -4.1           | -10.1          | -5.2           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 48.4%   |
| Net income pre   | 1,027.9        | 957.1          | 1,984.9        | 901.9          | 2,886.8        | 803.9          | 1,705.7        | 3,690.7        | 895.6          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -12.9%  |
| <b>EPS pre in €***</b>                                   | <b>2.36</b>    | <b>2.20</b>    | <b>4.57</b>    | <b>2.07</b>    | <b>6.64</b>    | <b>1.85</b>    | <b>3.92</b>    | <b>8.49</b>    | <b>2.06</b>    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -12.7%  |

Number of theoretical shares in million 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8 434.8

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

\*\* Only reflects impairments classified as adjustments.

\*\*\* For continuing operations.

**Breakdown of depreciation and amortization and adjustments**

| Group<br>€ million  | Division                                    | 2023     |              |              |              |              |                |              |              |                | 2024         |    |    |    |    |    |    |    |    | Change YoY |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         |        |        |
|---|---|----------|--------------|--------------|--------------|--------------|----------------|--------------|--------------|----------------|--------------|----|----|----|----|----|----|----|----|------------|----|----|----|----|----|--|--|--|--|--|--|--|--|--|---------|---------|--------|--------|
|   |   | Q1       | Q2           | H1           | Q3           | 9M           | Q4             | H2           | FY           | Q1             | Q2           | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1         | Q3 | 9M | Q4 | H2 | FY |  |  |  |  |  |  |  |  |  |         |         |        |        |
| <b>a) Depreciation and amortization</b>                     |   |          |              |              |              |              |                |              |              |                |              |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         |        |        |
| <b>Regular depreciation and amortization*</b>               |   | all      | 242.0        | 243.2        | 485.2        | 241.1        | 726.3          | 266.9        | 508.0        | 993.2          | 257.6        |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  | 6.5%    |         |        |        |
| <b>Impairments not adjusted</b>                             |   | all      | 0.0          | 4.2          | 4.2          | 0.0          | 4.2            | 11.8         | 11.8         | 16.0           | 9.2          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  | >1.000% |         |        |        |
| <b>Amortization of purchased intangible assets</b>          |   |          |              |              |              |              |                |              |              |                |              |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         |        |        |
|   | Life Science                                | LS       | 118.2        | 115.8        | 234.0        | 108.5        | 342.5          | 108.8        | 217.3        | 451.3          | 107.8        |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  | -8.7%   |         |        |        |
|   | Healthcare                                  | HC       | 1.5          | 1.6          | 3.2          | 1.7          | 4.8            | 1.7          | 3.3          | 6.5            | 1.6          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         | 3.7%    |        |        |
|   | Electronics                                 | EL       | 84.1         | 80.6         | 164.7        | 80.1         | 244.8          | 80.8         | 160.8        | 325.6          | 76.8         |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         | -8.7%   |        |        |
|   | <b>Total</b>                                |          | <b>203.8</b> | <b>198.1</b> | <b>401.9</b> | <b>190.3</b> | <b>592.2</b>   | <b>191.2</b> | <b>381.5</b> | <b>783.3</b>   | <b>186.2</b> |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  | -8.6%   |         |        |        |
| <b>Impairments (net)**</b>                                  |   | all      | 9.7          | 36.9         | 46.6         | 3.8          | 50.4           | 36.9         | 40.7         | 87.2           | 0.5          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         | -95.1%  |        |        |
| <b>Total depreciation and amortization</b>                  |   |          | <b>455.5</b> | <b>482.3</b> | <b>937.8</b> | <b>435.2</b> | <b>1,373.0</b> | <b>506.7</b> | <b>941.9</b> | <b>1,879.7</b> | <b>453.5</b> |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         | -0.4%   |        |        |
| <b>b) Adjustments</b>                                       |   |          |              |              |              |              |                |              |              |                |              |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         |        |        |
| <b>Acquisition costs</b>                                    |   |          | 9.2          | 4.8          | 14.0         | 3.7          | 17.7           | 0.8          | 4.4          | 18.5           | 2.5          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         | -72.7%  |        |        |
| <b>Restructuring costs</b>                                  |   |          |              |              |              |              |                |              |              |                |              |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         |        |        |
|   | Life Science                                | LS       | 0.4          | 1.8          | 2.2          | 4.3          | 6.5            | 23.1         | 27.4         | 29.6           | 18.0         |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         | >1.000% |        |        |
|   | Healthcare                                  | HC       | -7.3         | 12.0         | 4.7          | 2.6          | 7.3            | 24.2         | 26.8         | 31.6           | 5.3          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         | n.m.    |        |        |
|   | Electronics                                 | EL       | 2.2          | 6.9          | 9.1          | 9.9          | 18.9           | 41.0         | 50.9         | 60.0           | 4.1          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | 88.8%  |        |
|   | Corporate and Other                         | CO       | 49.0         | 18.5         | 67.6         | 7.9          | 75.4           | 52.0         | 59.8         | 127.4          | 17.2         |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | -65.0% |        |
|   | <b>Total</b>                                |          | <b>44.3</b>  | <b>39.3</b>  | <b>83.6</b>  | <b>24.6</b>  | <b>108.2</b>   | <b>140.3</b> | <b>164.9</b> | <b>248.5</b>   | <b>44.6</b>  |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | 0.7%   |        |
| <b>Integration costs/IT costs</b>                           |   |          |              |              |              |              |                |              |              |                |              |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         |        |        |
|   | Integration Cost                            | LS/EL/CO | 1.9          | 2.0          | 4.0          | 2.2          | 6.1            | 1.4          | 3.5          | 7.5            | 2.3          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | 18.4%  |        |
|   | ERP/HR systems                              | all      | 21.6         | 25.0         | 46.6         | 26.7         | 73.2           | 37.6         | 64.3         | 110.9          | 15.1         |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | -30.1% |        |
|   | <b>Total</b>                                |          | <b>23.5</b>  | <b>27.1</b>  | <b>50.6</b>  | <b>28.8</b>  | <b>79.4</b>    | <b>39.0</b>  | <b>67.8</b>  | <b>118.4</b>   | <b>17.4</b>  |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | -26.1% |        |
| <b>Gain (-)/ losses (+) on the divestment of businesses</b> |   |          |              |              |              |              |                |              |              |                |              |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         |        |        |
|   | Costs related to former business activities | CO       | 0.0          | 21.0         | 21.0         | -3.0         | 18.0           | -16.6        | -19.6        | 1.4            | 0.0          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | n.m.   |        |
|   | Costs related to former business activities | EL       | 0.0          | 0.0          | 0.0          | 0.0          | 0.0            | 0.0          | 0.0          | 0.0            | 0.0          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | n.m.   |        |
|   | Sale of CH, Allergopharma and others        | HC       | 0.3          | -3.9         | -3.6         | -45.8        | -49.4          | -3.4         | -49.2        | -52.8          | -4.8         |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | n.m.   |        |
|   | Costs related to former business activities | LS       | 0.0          | 0.0          | 0.0          | 0.0          | 0.0            | 0.0          | 0.0          | 0.0            | 0.0          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | n.m.   |        |
|   | <b>Total</b>                                |          | <b>0.3</b>   | <b>17.1</b>  | <b>17.4</b>  | <b>-48.8</b> | <b>-31.4</b>   | <b>-20.1</b> | <b>-68.8</b> | <b>-51.4</b>   | <b>-4.8</b>  |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | n.m.   |        |
| <b>Other one-time costs</b>                                 |   |          |              |              |              |              |                |              |              |                |              |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         |        |        |
|   | Others                                      | {        |              |              |              |              |                |              |              |                |              |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         |        |        |
|   |   | HC       | 0.0          | 0.0          | 0.0          | 0.0          | 0.0            | 0.0          | 0.0          | 0.0            | 0.0          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | n.m.   |        |
|   |   | LS       | 0.0          | 0.0          | 0.0          | 0.0          | 0.0            | 0.0          | 0.0          | 0.0            | 0.0          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | n.m.   |        |
|   |   | EL       | 0.0          | 0.0          | 0.0          | 0.0          | 0.0            | 0.0          | 0.0          | 0.0            | 0.0          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         |        | n.m.   |
|   |   | CO       | 19.2         | 13.2         | 32.4         | 18.9         | 51.3           | 4.8          | 23.7         | 56.1           | 9.4          |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         |        | -51.2% |
|   | <b>Total</b>                                |          | <b>19.2</b>  | <b>13.2</b>  | <b>32.4</b>  | <b>18.9</b>  | <b>51.3</b>    | <b>4.8</b>   | <b>23.7</b>  | <b>56.1</b>    | <b>9.4</b>   |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | -51.2% |        |
| <b>Total adjustments</b>                                    |   |          | <b>96.5</b>  | <b>101.5</b> | <b>198.0</b> | <b>27.2</b>  | <b>225.2</b>   | <b>164.9</b> | <b>192.1</b> | <b>390.1</b>   | <b>69.1</b>  |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |  |  |  |  |  |  |         |         | -28.4% |        |

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Life Science

€ million

|   | 2023           |                |                |                |                |                |                |                |                | 2024 |    |    |    |    |    |    |    |    | Change YoY |    |    |    |    |    |  |  |  |        |         |  |
|---|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|------|----|----|----|----|----|----|----|----|------------|----|----|----|----|----|--|--|--|--------|---------|--|
|   | Q1             | Q2             | H1             | Q3             | 9M             | Q4             | H2             | FY             | Q1             | Q2   | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1         | Q3 | 9M | Q4 | H2 | FY |  |  |  |        |         |  |
| <b>Net sales</b>                                | <b>2,486.8</b> | <b>2,353.5</b> | <b>4,840.3</b> | <b>2,190.9</b> | <b>7,031.2</b> | <b>2,249.4</b> | <b>4,440.2</b> | <b>9,280.5</b> | <b>2,143.7</b> |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  | -13.8% |         |  |
| Cost of sales                                   | -999.2         | -1,078.2       | -2,077.5       | -1,031.1       | -3,108.6       | -1,127.6       | -2,158.8       | -4,236.3       | -987.6         |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  | -1.2%  |         |  |
| thereof amortization of intangible assets       | -13.3          | -13.5          | -26.8          | -8.3           | -35.1          | -7.2           | -15.4          | -42.2          | -7.1           |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  | -46.7% |         |  |
| Gross profit                                    | 1,487.5        | 1,275.3        | 2,762.8        | 1,159.7        | 3,922.6        | 1,121.7        | 2,281.4        | 5,044.3        | 1,156.2        |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  | -22.3% |         |  |
| <i>in % of net sales</i>                        | <i>59.8%</i>   | <i>54.2%</i>   | <i>57.1%</i>   | <i>52.9%</i>   | <i>55.8%</i>   | <i>49.9%</i>   | <i>51.4%</i>   | <i>54.4%</i>   | <i>53.9%</i>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        |         |  |
| SG&A  | -711.3         | -720.8         | -1,432.2       | -673.2         | -2,105.4       | -692.4         | -1,365.7       | -2,797.8       | -683.3         |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -3.9%   |  |
| <i>in % of net sales</i>                        | <i>28.6%</i>   | <i>30.6%</i>   | <i>29.6%</i>   | <i>30.7%</i>   | <i>29.9%</i>   | <i>30.8%</i>   | <i>30.8%</i>   | <i>30.1%</i>   | <i>31.9%</i>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        |         |  |
| Marketing and selling expenses                  | -567.5         | -566.3         | -1,133.8       | -555.7         | -1,689.5       | -555.3         | -1,110.9       | -2,244.7       | -550.6         |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -3.0%   |  |
| thereof amortization of intangible assets (M&S) | -101.4         | -100.4         | -201.8         | -98.2          | -300.0         | -99.5          | -197.7         | -399.5         | -98.7          |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -2.7%   |  |
| Administration expenses                         | -105.0         | -102.8         | -207.7         | -102.7         | -310.5         | -114.6         | -217.4         | -425.1         | -111.9         |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | 6.6%    |  |
| Impairment losses and reversals (IFRS 9)        | -1.1           | -1.2           | -2.3           | -0.1           | -2.4           | 0.3            | 0.2            | -2.1           | -1.0           |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -4.1%   |  |
| Other operating expenses/income                 | -37.8          | -50.6          | -88.3          | -14.8          | -103.1         | -22.8          | -37.6          | -125.9         | -19.7          |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -47.7%  |  |
| Impairments**                                   | 0.0            | -31.9          | -31.9          | 0.0            | -31.9          | -1.8           | -1.8           | -33.7          | 0.0            |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -100.0% |  |
| Research and development costs                  | -103.8         | -99.1          | -203.0         | -90.4          | -293.3         | -103.1         | -193.4         | -396.4         | -95.4          |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -8.1%   |  |
| <i>in % of net sales</i>                        | <i>4.2%</i>    | <i>4.2%</i>    | <i>4.2%</i>    | <i>4.1%</i>    | <i>4.2%</i>    | <i>4.6%</i>    | <i>4.4%</i>    | <i>4.3%</i>    | <i>4.5%</i>    |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        |         |  |
| thereof amortization of intangible assets (R&D) | -3.4           | -2.0           | -5.4           | -2.1           | -7.5           | -2.1           | -4.1           | -9.5           | -2.1           |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -38.9%  |  |
| <b>EBIT</b>                                     | <b>672.4</b>   | <b>455.3</b>   | <b>1,127.7</b> | <b>396.1</b>   | <b>1,523.8</b> | <b>326.2</b>   | <b>722.3</b>   | <b>1,850.0</b> | <b>377.4</b>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -43.9%  |  |
| <i>in % of net sales</i>                        | <i>27.0%</i>   | <i>19.3%</i>   | <i>23.3%</i>   | <i>18.1%</i>   | <i>21.7%</i>   | <i>14.5%</i>   | <i>16.3%</i>   | <i>19.9%</i>   | <i>17.6%</i>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        |         |  |
| Depreciation and amortization                   | 211.7          | 243.1          | 454.8          | 204.6          | 659.4          | 222.0          | 426.6          | 881.4          | 207.4          |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -2.0%   |  |
| <b>EBITDA</b>                                   | <b>884.0</b>   | <b>698.5</b>   | <b>1,582.5</b> | <b>600.7</b>   | <b>2,183.3</b> | <b>548.2</b>   | <b>1,148.9</b> | <b>2,731.4</b> | <b>584.8</b>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -33.8%  |  |
| <i>in % of net sales</i>                        | <i>35.5%</i>   | <i>29.7%</i>   | <i>32.7%</i>   | <i>27.4%</i>   | <i>31.1%</i>   | <i>24.4%</i>   | <i>25.9%</i>   | <i>29.4%</i>   | <i>27.3%</i>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        |         |  |
| <b>EBITDA pre</b>                               | <b>900.6</b>   | <b>711.9</b>   | <b>1,612.5</b> | <b>615.1</b>   | <b>2,227.6</b> | <b>592.0</b>   | <b>1,207.1</b> | <b>2,819.6</b> | <b>611.2</b>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -32.1%  |  |
| <i>in % of net sales</i>                        | <i>36.2%</i>   | <i>30.2%</i>   | <i>33.3%</i>   | <i>28.1%</i>   | <i>31.7%</i>   | <i>26.3%</i>   | <i>27.2%</i>   | <i>30.4%</i>   | <i>28.5%</i>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        |         |  |
| <b>Reconciliation to EBITDA pre</b>             |                |                |                |                |                |                |                |                |                |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        |         |  |
| EBITDA  | 884.0          | 698.5          | 1,582.5        | 600.7          | 2,183.3        | 548.2          | 1,148.9        | 2,731.4        | 584.8          |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -33.8%  |  |
| <b>Adjustments</b>                              |                |                |                |                |                |                |                |                |                |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        |         |  |
| thereof: Cost of Sales                          | 0.2            | -0.1           | 0.1            | 2.8            | 3.0            | 3.2            | 6.1            | 6.2            | 0.8            |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | 276.6%  |  |
| thereof: Marketing and selling expenses         | -1.2           | 0.3            | -0.9           | 0.3            | -0.6           | 12.9           | 13.2           | 12.3           | 5.3            |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | n.m.    |  |
| thereof: Administration expenses                | 11.1           | 12.0           | 23.0           | 9.0            | 32.0           | 20.8           | 29.8           | 52.8           | 17.1           |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | 54.9%   |  |
| thereof: Other operating expenses/income        | 6.4            | 0.5            | 6.9            | 2.3            | 9.2            | 4.6            | 6.9            | 13.8           | 2.6            |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -59.8%  |  |
| thereof: Research and development               | 0.0            | 0.7            | 0.8            | 0.0            | 0.8            | 2.3            | 2.3            | 3.1            | 0.6            |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | >1.000% |  |
| <b>Total</b>                                    | <b>16.5</b>    | <b>13.4</b>    | <b>29.9</b>    | <b>14.4</b>    | <b>44.4</b>    | <b>43.8</b>    | <b>58.2</b>    | <b>88.2</b>    | <b>26.4</b>    |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | 59.4%   |  |
| <b>EBITDA pre</b>                               | <b>900.6</b>   | <b>711.9</b>   | <b>1,612.5</b> | <b>615.1</b>   | <b>2,227.6</b> | <b>592.0</b>   | <b>1,207.1</b> | <b>2,819.6</b> | <b>611.2</b>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |  |  |  |        | -32.1%  |  |

Due to rounding the sum of individual values may not add up to totals presented.

\*\* Only reflects impairments classified as adjustments.

**Detailed reconciliation - Life Science**

| € million   | 2023         |              |                |              |                |              |                |                |              | 2024 |    |    |    |    |    |    |    |    | Change YoY |    |    |    |    |    |    |         |
|---|--------------|--------------|----------------|--------------|----------------|--------------|----------------|----------------|--------------|------|----|----|----|----|----|----|----|----|------------|----|----|----|----|----|----|---------|
|   | Q1           | Q2           | H1             | Q3           | 9M             | Q4           | H2             | FY             |              | Q1   | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2         | H1 | Q3 | 9M | Q4 | H2 | FY |         |
| <b>EBIT</b>   | <b>672.4</b> | <b>455.3</b> | <b>1,127.7</b> | <b>396.1</b> | <b>1,523.8</b> | <b>326.2</b> | <b>722.3</b>   | <b>1,850.0</b> | <b>377.4</b> |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | -43.9%  |
| Regular depreciation and amortization*                      | 93.5         | 95.4         | 188.9          | 96.1         | 285.0          | 111.4        | 207.5          | 396.4          | 99.5         |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | 6.5%    |
| Impairments not adjusted                                    | 0.0          | 0.0          | 0.0            | 0.0          | 0.0            | 0.0          | 0.0            | 0.0            | 0.0          |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | -100.0% |
| Amortization of purchased intangible assets                 | 118.2        | 115.8        | 234.0          | 108.5        | 342.5          | 108.8        | 217.3          | 451.3          | 107.8        |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | -8.7%   |
| Impairments (net)**   | 0.0          | 31.9         | 31.9           | 0.0          | 31.9           | 1.8          | 1.8            | 33.7           | 0.0          |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | -100.0% |
| <b>Total depreciation and amortization</b>                  | <b>211.7</b> | <b>243.1</b> | <b>454.8</b>   | <b>204.6</b> | <b>659.4</b>   | <b>222.0</b> | <b>426.6</b>   | <b>881.4</b>   | <b>207.4</b> |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | -2.0%   |
| <b>EBITDA</b>   | <b>884.0</b> | <b>698.5</b> | <b>1,582.5</b> | <b>600.7</b> | <b>2,183.3</b> | <b>548.2</b> | <b>1,148.9</b> | <b>2,731.4</b> | <b>584.8</b> |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | -33.8%  |
| <b>Adjustments</b>  |              |              |                |              |                |              |                |                |              |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |         |
| <b>Acquisition costs</b>                                    | <b>5.0</b>   | <b>-0.3</b>  | <b>4.8</b>     | <b>0.0</b>   | <b>4.8</b>     | <b>0.8</b>   | <b>0.8</b>     | <b>5.6</b>     | <b>1.1</b>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | -78.4%  |
| <b>Restructuring costs</b>                                  |              |              |                |              |                |              |                |                |              |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |         |
| Restructuring costs   | 0.4          | 1.8          | 2.2            | 4.3          | 6.5            | 23.1         | 27.4           | 29.6           | 18.0         |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | >1.000% |
| <b>Total</b>  | <b>0.4</b>   | <b>1.8</b>   | <b>2.2</b>     | <b>4.3</b>   | <b>6.5</b>     | <b>23.1</b>  | <b>27.4</b>    | <b>29.6</b>    | <b>18.0</b>  |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | >1.000% |
| <b>Integration costs/IT costs</b>                           |              |              |                |              |                |              |                |                |              |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |         |
| Integration Cost  | 0.7          | 1.0          | 1.7            | 0.9          | 2.7            | 0.8          | 1.7            | 3.5            | 1.0          |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | 40.1%   |
| ERP/HR systems  | 10.3         | 10.9         | 21.2           | 9.2          | 30.4           | 19.1         | 28.3           | 49.5           | 6.2          |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | -40.4%  |
| <b>Total</b>  | <b>11.1</b>  | <b>11.8</b>  | <b>22.9</b>    | <b>10.1</b>  | <b>33.1</b>    | <b>19.9</b>  | <b>30.0</b>    | <b>53.0</b>    | <b>7.2</b>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | -35.0%  |
| <b>Gain (-)/ losses (+) on the divestment of businesses</b> |              |              |                |              |                |              |                |                |              |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |         |
| Costs related to former business activities                 | 0.0          | 0.0          | 0.0            | 0.0          | 0.0            | 0.0          | 0.0            | 0.0            | 0.0          |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | n.m.    |
| <b>Total</b>  | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>     | <b>0.0</b>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | n.m.    |
| <b>Other one-time costs</b>                                 |              |              |                |              |                |              |                |                |              |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |         |
| Others  | 0.0          | 0.0          | 0.0            | 0.0          | 0.0            | 0.0          | 0.0            | 0.0            | 0.0          |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | n.m.    |
| <b>Total</b>  | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>     | <b>0.0</b>   |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | n.m.    |
| <b>Total adjustments</b>                                    | <b>16.5</b>  | <b>13.4</b>  | <b>29.9</b>    | <b>14.4</b>  | <b>44.4</b>    | <b>43.8</b>  | <b>58.2</b>    | <b>88.2</b>    | <b>26.4</b>  |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | 59.4%   |
| <b>EBITDA pre</b>   | <b>900.6</b> | <b>711.9</b> | <b>1,612.5</b> | <b>615.1</b> | <b>2,227.6</b> | <b>592.0</b> | <b>1,207.1</b> | <b>2,819.6</b> | <b>611.2</b> |      |    |    |    |    |    |    |    |    |            |    |    |    |    |    |    | -32.1%  |

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

\*\* Only reflects impairments classified as adjustments.

## Income Statement Merck KGaA, Darmstadt, Germany

## Healthcare

€ million

|   | 2023           |                |                |                |                |                |                |                | 2024           |    |    |    |    |    |    |    | Change YoY |    |    |    |    |    |    |    |  |  |         |      |
|---|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----|----|----|----|----|----|----|------------|----|----|----|----|----|----|----|--|--|---------|------|
|   | Q1             | Q2             | H1             | Q3             | 9M             | Q4             | H2             | FY             | Q1             | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1         | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |  |  |         |      |
| <b>Net sales</b>                                | <b>1,905.5</b> | <b>2,049.5</b> | <b>3,955.0</b> | <b>2,066.3</b> | <b>6,021.3</b> | <b>2,031.9</b> | <b>4,098.2</b> | <b>8,053.2</b> | <b>2,047.7</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 7.5%    |      |
| Cost of sales                                   | -446.6         | -485.9         | -932.6         | -540.0         | -1,472.6       | -556.4         | -1,096.4       | -2,029.0       | -543.3         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 21.6%   |      |
| thereof amortization of intangible assets       | -1.2           | -1.2           | -2.3           | -1.2           | -3.5           | -1.1           | -2.3           | -4.6           | -1.1           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | -3.0%   |      |
| Gross profit                                    | 1,458.9        | 1,563.6        | 3,022.4        | 1,526.2        | 4,548.7        | 1,475.5        | 3,001.8        | 6,024.2        | 1,504.4        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 3.1%    |      |
| <i>in % of net sales</i>                        | 76.6%          | 76.3%          | 76.4%          | 73.9%          | 75.5%          | 72.6%          | 73.2%          | 74.8%          | 73.5%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  |         |      |
| SG&A  | -543.9         | -546.4         | -1,090.2       | -481.7         | -1,571.9       | -570.7         | -1,052.4       | -2,142.6       | -488.9         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | -10.1%  |      |
| <i>in % of net sales</i>                        | 28.5%          | 26.7%          | 27.6%          | 23.3%          | 26.1%          | 28.1%          | 25.7%          | 26.6%          | 23.9%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  |         |      |
| Marketing and selling expenses                  | -380.6         | -422.4         | -803.0         | -405.5         | -1,208.5       | -459.1         | -864.6         | -1,667.6       | -398.2         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 4.6%    |      |
| thereof amortization of intangible assets (M&S) | -0.3           | -0.4           | -0.7           | -0.5           | -1.2           | -0.5           | -0.9           | -1.6           | -0.4           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 29.2%   |      |
| Administration expenses                         | -75.5          | -79.3          | -154.8         | -78.8          | -233.6         | -80.2          | -159.0         | -313.8         | -75.2          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | -0.4%   |      |
| Impairment losses and reversals (IFRS 9)        | -1.0           | -8.4           | -9.4           | -28.4          | -37.8          | -3.0           | -31.3          | -40.8          | 1.9            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | n.m.    |      |
| Other operating expenses/income                 | -86.8          | -36.2          | -123.0         | 30.9           | -92.0          | -28.4          | 2.5            | -120.5         | -17.4          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | -79.9%  |      |
| Impairments**                                   | 0.6            | 0.0            | 0.6            | 0.0            | 0.6            | -10.5          | -10.5          | -9.9           | 0.0            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | -100.0% |      |
| Research and development costs                  | -395.3         | -401.5         | -796.7         | -391.3         | -1,188.0       | -469.0         | -860.3         | -1,657.0       | -397.5         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 0.6%    |      |
| <i>in % of net sales</i>                        | 20.7%          | 19.6%          | 20.1%          | 18.9%          | 19.7%          | 23.1%          | 21.0%          | 20.6%          | 19.4%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  |         |      |
| thereof amortization of intangible assets (R&D) | -0.1           | -0.1           | -0.1           | -0.1           | -0.2           | -0.1           | -0.1           | -0.2           | -0.1           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  |         | 0.0% |
| <b>EBIT</b>                                     | <b>519.7</b>   | <b>615.8</b>   | <b>1,135.5</b> | <b>653.2</b>   | <b>1,788.7</b> | <b>435.9</b>   | <b>1,089.1</b> | <b>2,224.6</b> | <b>618.0</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 18.9%   |      |
| <i>in % of net sales</i>                        | 27.3%          | 30.0%          | 28.7%          | 31.6%          | 29.7%          | 21.5%          | 26.6%          | 27.6%          | 30.2%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  |         |      |
| Depreciation and amortization                   | 72.9           | 76.2           | 149.1          | 70.2           | 219.4          | 100.6          | 170.9          | 320.0          | 88.3           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 21.1%   |      |
| <b>EBITDA</b>                                   | <b>592.6</b>   | <b>692.0</b>   | <b>1,284.6</b> | <b>723.4</b>   | <b>2,008.1</b> | <b>536.5</b>   | <b>1,259.9</b> | <b>2,544.6</b> | <b>706.3</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 19.2%   |      |
| <i>in % of net sales</i>                        | 31.1%          | 33.8%          | 32.5%          | 35.0%          | 33.3%          | 26.4%          | 30.7%          | 31.6%          | 34.5%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  |         |      |
| <b>EBITDA pre</b>                               | <b>589.6</b>   | <b>703.6</b>   | <b>1,293.2</b> | <b>685.4</b>   | <b>1,978.5</b> | <b>564.5</b>   | <b>1,249.9</b> | <b>2,543.1</b> | <b>708.0</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 20.1%   |      |
| <i>in % of net sales</i>                        | 30.9%          | 34.3%          | 32.7%          | 33.2%          | 32.9%          | 27.8%          | 30.5%          | 31.6%          | 34.6%          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  |         |      |
| <b>Reconciliation to EBITDA pre</b>             |                |                |                |                |                |                |                |                |                |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  |         |      |
| EBITDA  | 592.6          | 692.0          | 1,284.6        | 723.4          | 2,008.1        | 536.5          | 1,259.9        | 2,544.6        | 706.3          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 19.2%   |      |
| <b>Adjustments</b>                              |                |                |                |                |                |                |                |                |                |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  |         |      |
| thereof: Cost of Sales                          | 0.2            | -1.7           | -1.5           | 0.3            | -1.3           | -0.1           | 0.2            | -1.3           | 0.1            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | -52.4%  |      |
| thereof: Marketing and selling expenses         | 0.3            | 4.6            | 4.9            | 5.7            | 10.6           | 18.3           | 23.9           | 28.8           | 3.7            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | >1.000% |      |
| thereof: Administration expenses                | 4.0            | 3.5            | 7.4            | 5.1            | 12.5           | 7.6            | 12.6           | 20.1           | 1.1            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | -72.0%  |      |
| thereof: Other operating expenses/income        | 0.3            | 0.3            | 0.6            | -49.3          | -48.7          | -2.3           | -51.5          | -51.0          | -8.0           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | n.m.    |      |
| thereof: Research and development               | -7.8           | 5.0            | -2.8           | 0.2            | -2.6           | 4.5            | 4.7            | 1.9            | 4.8            |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | n.m.    |      |
| <b>Total</b>                                    | <b>-3.0</b>    | <b>11.6</b>    | <b>8.6</b>     | <b>-38.1</b>   | <b>-29.5</b>   | <b>28.0</b>    | <b>-10.1</b>   | <b>-1.5</b>    | <b>1.7</b>     |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | n.m.    |      |
| <b>EBITDA pre</b>                               | <b>589.6</b>   | <b>703.6</b>   | <b>1,293.2</b> | <b>685.4</b>   | <b>1,978.5</b> | <b>564.5</b>   | <b>1,249.9</b> | <b>2,543.1</b> | <b>708.0</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |  | 20.1%   |      |

Due to rounding the sum of individual values may not add up to totals presented.



**Detailed reconciliation - Healthcare**

| € million   | 2023         |              |                |              |                |              |                |                | 2024         |    |    |    |    |    |    |    | Change YoY |    |    |    |    |    |    |    |  |         |         |
|---|--------------|--------------|----------------|--------------|----------------|--------------|----------------|----------------|--------------|----|----|----|----|----|----|----|------------|----|----|----|----|----|----|----|--|---------|---------|
|   | Q1           | Q2           | H1             | Q3           | 9M             | Q4           | H2             | FY             | Q1           | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1         | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |  |         |         |
| <b>EBIT</b>   | <b>519.7</b> | <b>615.8</b> | <b>1,135.5</b> | <b>653.2</b> | <b>1,788.7</b> | <b>435.9</b> | <b>1,089.1</b> | <b>2,224.6</b> | <b>618.0</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 18.9%   |         |
| Regular depreciation and amortization*                      | 71.9         | 70.4         | 142.3          | 68.5         | 210.9          | 76.7         | 145.3          | 287.6          | 77.7         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 8.0%    |         |
| Impairments not adjusted                                    | 0.0          | 4.2          | 4.2            | 0.0          | 4.2            | 11.8         | 11.8           | 16.0           | 9.0          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | >1.000% |         |
| Amortization of purchased intangible assets                 | 1.5          | 1.6          | 3.2            | 1.7          | 4.8            | 1.7          | 3.3            | 6.5            | 1.6          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 3.7%    |         |
| Impairments (net)**   | -0.6         | 0.0          | -0.6           | 0.0          | -0.6           | 10.5         | 10.5           | 9.9            | 0.0          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -100.0% |         |
| <b>Total depreciation and amortization</b>                  | <b>72.9</b>  | <b>76.2</b>  | <b>149.1</b>   | <b>70.2</b>  | <b>219.4</b>   | <b>100.6</b> | <b>170.9</b>   | <b>320.0</b>   | <b>88.3</b>  |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 21.1%   |         |
| <b>EBITDA</b>   | <b>592.6</b> | <b>692.0</b> | <b>1,284.6</b> | <b>723.4</b> | <b>2,008.1</b> | <b>536.5</b> | <b>1,259.9</b> | <b>2,544.6</b> | <b>706.3</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 19.2%   |         |
| <b>Adjustments</b>  |              |              |                |              |                |              |                |                |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |         |
| <b>Acquisition costs</b>                                    | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>     | <b>0.0</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | n.m.    |         |
| <b>Restructuring costs</b>                                  |              |              |                |              |                |              |                |                |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |         |
| Restructuring costs   | -7.3         | 12.0         | 4.7            | 2.6          | 7.3            | 24.2         | 26.8           | 31.6           | 5.3          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | n.m.    |         |
| <b>Total</b>  | <b>-7.3</b>  | <b>12.0</b>  | <b>4.7</b>     | <b>2.6</b>   | <b>7.3</b>     | <b>24.2</b>  | <b>26.8</b>    | <b>31.6</b>    | <b>5.3</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | n.m.    |         |
| <b>Integration costs/IT costs</b>                           |              |              |                |              |                |              |                |                |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |         |
| Integration Cost  | 0.0          | 0.0          | 0.0            | 0.0          | 0.0            | 0.0          | 0.0            | 0.0            | 0.0          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | n.m.    |         |
| ERP/HR systems  | 4.0          | 3.5          | 7.4            | 5.1          | 12.5           | 7.2          | 12.3           | 19.7           | 1.1          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -72.0%  |         |
| <b>Total</b>  | <b>4.0</b>   | <b>3.5</b>   | <b>7.4</b>     | <b>5.1</b>   | <b>12.5</b>    | <b>7.2</b>   | <b>12.3</b>    | <b>19.7</b>    | <b>1.1</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | -72.0%  |         |
| <b>Gain (-)/ losses (+) on the divestment of businesses</b> |              |              |                |              |                |              |                |                |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |         |
| Sale of Kuvan and Biosimilars                               | 0.0          | -7.6         | -7.6           | -50.5        | -58.1          | -4.0         | -54.5          | -62.1          | -4.8         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         | >1.000% |
| Sale of Consumer Health                                     | 0.0          | 4.3          | 4.3            | 4.7          | 9.0            | 0.6          | 5.3            | 9.6            | 0.0          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 3.2%    |         |
| Sale of Allergopharma                                       | 0.0          | 0.0          | 0.0            | 0.0          | 0.0            | 0.0          | 0.0            | 0.0            | 0.0          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | n.m.    |         |
| Others  | 0.0          | 0.0          | 0.0            | 0.0          | 0.0            | 0.0          | 0.0            | 0.0            | 0.0          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | n.m.    |         |
| <b>Total</b>  | <b>0.3</b>   | <b>-3.9</b>  | <b>-3.6</b>    | <b>-45.8</b> | <b>-49.4</b>   | <b>-3.4</b>  | <b>-49.2</b>   | <b>-52.8</b>   | <b>-4.8</b>  |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | n.m.    |         |
| <b>Other one-time costs</b>                                 |              |              |                |              |                |              |                |                |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         |         |
| Others  | 0.0          | 0.0          | 0.0            | 0.0          | 0.0            | 0.0          | 0.0            | 0.0            | 0.0          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         | n.m.    |
| <b>Total</b>  | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>   | <b>0.0</b>     | <b>0.0</b>     | <b>0.0</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  |         | n.m.    |
| <b>Total adjustments</b>                                    | <b>-3.0</b>  | <b>11.6</b>  | <b>8.6</b>     | <b>-38.1</b> | <b>-29.5</b>   | <b>28.0</b>  | <b>-10.1</b>   | <b>-1.5</b>    | <b>1.7</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | n.m.    |         |
| <b>EBITDA pre</b>   | <b>589.6</b> | <b>703.6</b> | <b>1,293.2</b> | <b>685.4</b> | <b>1,978.5</b> | <b>564.5</b> | <b>1,249.9</b> | <b>2,543.1</b> | <b>708.0</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |  | 20.1%   |         |

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

\*\* Only reflects impairments classified as adjustments.

**Income Statement Merck KGaA, Darmstadt, Germany**

| Electronics<br>€ million                        | 2023         |              |                |              |                |              |                |                | 2024         |    |    |    |    |    |    |    | Change YoY |    |    |    |    |    |    |    |      |         |
|---|--------------|--------------|----------------|--------------|----------------|--------------|----------------|----------------|--------------|----|----|----|----|----|----|----|------------|----|----|----|----|----|----|----|------|---------|
|   | Q1           | Q2           | H1             | Q3           | 9M             | Q4           | H2             | FY             | Q1           | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1         | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |      |         |
| <b>Net sales</b>                                | <b>900.7</b> | <b>899.3</b> | <b>1,800.0</b> | <b>915.9</b> | <b>2,715.9</b> | <b>943.2</b> | <b>1,859.1</b> | <b>3,659.2</b> | <b>928.4</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | 3.1% |         |
| Cost of sales                                   | -525.8       | -572.2       | -1,097.9       | -592.2       | -1,690.1       | -641.9       | -1,234.1       | -2,332.0       | -580.1       |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | 10.3%   |
| thereof amortization of intangible assets       | -33.6        | -31.5        | -65.2          | -30.9        | -96.1          | -30.3        | -61.2          | -126.4         | -30.0        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -10.8%  |
| Gross profit                                    | 374.9        | 327.2        | 702.1          | 323.7        | 1,025.8        | 301.3        | 625.0          | 1,327.2        | 348.3        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -7.1%   |
| <i>in % of net sales</i>                        | <i>41.6%</i> | <i>36.4%</i> | <i>39.0%</i>   | <i>35.3%</i> | <i>37.8%</i>   | <i>31.9%</i> | <i>33.6%</i>   | <i>36.3%</i>   | <i>37.5%</i> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      |         |
| SG&A  | -215.1       | -142.5       | -357.7         | -196.7       | -554.3         | -227.9       | -424.6         | -782.2         | -180.0       |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -16.3%  |
| <i>in % of net sales</i>                        | <i>23.9%</i> | <i>15.8%</i> | <i>19.9%</i>   | <i>21.5%</i> | <i>20.4%</i>   | <i>24.2%</i> | <i>22.8%</i>   | <i>21.4%</i>   | <i>19.4%</i> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      |         |
| Marketing and selling expenses                  | -158.2       | -147.6       | -305.8         | -143.7       | -449.5         | -141.3       | -285.0         | -590.8         | -137.7       |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -12.9%  |
| thereof amortization of intangible assets (M&S) | -49.5        | -48.2        | -97.6          | -48.1        | -145.8         | -49.3        | -97.4          | -195.0         | -45.6        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -7.9%   |
| Administration expenses                         | -33.0        | -35.1        | -68.1          | -40.0        | -108.0         | -39.1        | -79.1          | -147.1         | -37.2        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | 12.8%   |
| Impairment losses and reversals (IFRS 9)        | -0.1         | -0.1         | -0.2           | 0.1          | -0.1           | 0.0          | 0.1            | -0.1           | 0.1          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | n.m.    |
| Other operating expenses/income                 | -23.8        | 40.2         | 16.4           | -13.1        | 3.3            | -47.5        | -60.6          | -44.2          | -5.2         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -78.3%  |
| Impairments**                                   | -10.3        | -5.0         | -15.3          | -3.7         | -18.9          | -23.3        | -27.0          | -42.3          | -0.5         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -95.3%  |
| Research and development costs                  | -74.1        | -74.5        | -148.7         | -74.7        | -223.4         | -74.0        | -148.7         | -297.4         | -73.1        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -1.5%   |
| <i>in % of net sales</i>                        | <i>8.2%</i>  | <i>8.3%</i>  | <i>8.3%</i>    | <i>8.2%</i>  | <i>8.2%</i>    | <i>7.8%</i>  | <i>8.0%</i>    | <i>8.1%</i>    | <i>7.9%</i>  |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      |         |
| thereof amortization of intangible assets (R&D) | -1.0         | -0.9         | -1.9           | -1.0         | -3.0           | -1.2         | -2.3           | -4.2           | -1.1         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | 19.5%   |
| <b>EBIT</b>                                     | <b>85.7</b>  | <b>110.1</b> | <b>195.8</b>   | <b>52.3</b>  | <b>248.1</b>   | <b>-0.5</b>  | <b>51.7</b>    | <b>247.5</b>   | <b>95.2</b>  |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | 11.1%   |
| <i>in % of net sales</i>                        | <i>9.5%</i>  | <i>12.2%</i> | <i>10.9%</i>   | <i>5.7%</i>  | <i>9.1%</i>    | <i>-0.1%</i> | <i>2.8%</i>    | <i>6.8%</i>    | <i>10.3%</i> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      |         |
| Depreciation and amortization                   | 142.6        | 134.7        | 277.3          | 133.5        | 410.8          | 157.4        | 290.9          | 568.2          | 129.8        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -9.0%   |
| <b>EBITDA</b>                                   | <b>228.2</b> | <b>244.8</b> | <b>473.1</b>   | <b>185.8</b> | <b>658.8</b>   | <b>156.9</b> | <b>342.6</b>   | <b>815.7</b>   | <b>224.9</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -1.4%   |
| <i>in % of net sales</i>                        | <i>25.3%</i> | <i>27.2%</i> | <i>26.3%</i>   | <i>20.3%</i> | <i>24.3%</i>   | <i>16.6%</i> | <i>18.4%</i>   | <i>22.3%</i>   | <i>24.2%</i> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      |         |
| <b>EBITDA pre</b>                               | <b>237.3</b> | <b>261.7</b> | <b>499.1</b>   | <b>207.9</b> | <b>707.0</b>   | <b>206.0</b> | <b>413.9</b>   | <b>913.0</b>   | <b>236.6</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -0.3%   |
| <i>in % of net sales</i>                        | <i>26.4%</i> | <i>29.1%</i> | <i>27.7%</i>   | <i>22.7%</i> | <i>26.0%</i>   | <i>21.8%</i> | <i>22.3%</i>   | <i>25.0%</i>   | <i>25.5%</i> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      |         |
| <b>Reconciliation to EBITDA pre</b>             |              |              |                |              |                |              |                |                |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      |         |
| EBITDA  | 228.2        | 244.8        | 473.1          | 185.8        | 658.8          | 156.9        | 342.6          | 815.7          | 224.9        |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -1.4%   |
| <b>Adjustments</b>                              |              |              |                |              |                |              |                |                |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      |         |
| thereof: Cost of Sales                          | 2.0          | 5.9          | 8.0            | 7.3          | 15.3           | 21.8         | 29.1           | 37.1           | 3.2          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | 58.2%   |
| thereof: Marketing and selling expenses         | 0.0          | 0.5          | 0.5            | 2.0          | 2.5            | 0.8          | 2.8            | 3.3            | 0.1          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | >1.000% |
| thereof: Administration expenses                | 2.0          | 3.6          | 5.7            | 7.7          | 13.3           | 15.4         | 23.1           | 28.7           | 4.7          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | 135.0%  |
| thereof: Other operating expenses/income        | 5.1          | 6.4          | 11.5           | 4.9          | 16.4           | 11.0         | 16.0           | 27.5           | 3.4          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -33.7%  |
| thereof: Research and development               | -0.1         | 0.5          | 0.4            | 0.3          | 0.7            | 0.1          | 0.4            | 0.8            | 0.2          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | n.m.    |
| <b>Total</b>                                    | <b>9.1</b>   | <b>16.9</b>  | <b>26.0</b>    | <b>22.1</b>  | <b>48.1</b>    | <b>49.2</b>  | <b>71.3</b>    | <b>97.3</b>    | <b>11.7</b>  |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | 28.3%   |
| <b>EBITDA pre</b>                               | <b>237.3</b> | <b>261.7</b> | <b>499.1</b>   | <b>207.9</b> | <b>707.0</b>   | <b>206.0</b> | <b>413.9</b>   | <b>913.0</b>   | <b>236.6</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |      | -0.3%   |

Due to rounding the sum of individual values may not add up to totals presented.

\*\* Only reflects impairments classified as adjustments.

**Detailed reconciliation - Electronics**

| € million   | 2023         |              |              |              |              |              |              |              | 2024         |    |    |    |    |    |    |    | Change YoY |    |    |    |    |    |    |    |         |  |
|---|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|----|----|----|----|----|----|----|------------|----|----|----|----|----|----|----|---------|--|
|   | Q1           | Q2           | H1           | Q3           | 9M           | Q4           | H2           | FY           | Q1           | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1         | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |         |  |
| <b>EBIT</b>   | <b>85.7</b>  | <b>110.1</b> | <b>195.8</b> | <b>52.3</b>  | <b>248.1</b> | <b>-0.5</b>  | <b>51.7</b>  | <b>247.5</b> | <b>95.2</b>  |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | 11.1%   |  |
| Regular depreciation and amortization*                      | 48.2         | 49.1         | 97.3         | 49.7         | 147.0        | 53.3         | 103.0        | 200.3        | 52.5         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | 9.0%    |  |
| Impairments not adjusted                                    | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.2          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | >1.000% |  |
| Amortization of purchased intangible assets                 | 84.1         | 80.6         | 164.7        | 80.1         | 244.8        | 80.8         | 160.8        | 325.6        | 76.8         |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | -8.7%   |  |
| Impairments (net)**   | 10.3         | 5.0          | 15.3         | 3.7          | 18.9         | 23.3         | 27.0         | 42.3         | 0.5          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | -95.3%  |  |
| <b>Total depreciation and amortization</b>                  | <b>142.6</b> | <b>134.7</b> | <b>277.3</b> | <b>133.5</b> | <b>410.8</b> | <b>157.4</b> | <b>290.9</b> | <b>568.2</b> | <b>129.8</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | -9.0%   |  |
| <b>EBITDA</b>   | <b>228.2</b> | <b>244.8</b> | <b>473.1</b> | <b>185.8</b> | <b>658.8</b> | <b>156.9</b> | <b>342.6</b> | <b>815.7</b> | <b>224.9</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | -1.4%   |  |
| <b>Adjustments</b>  |              |              |              |              |              |              |              |              |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |         |  |
| <b>Acquisition costs</b>                                    | <b>4.2</b>   | <b>5.1</b>   | <b>9.2</b>   | <b>3.7</b>   | <b>12.9</b>  | <b>0.0</b>   | <b>3.6</b>   | <b>12.9</b>  | <b>1.4</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | -65.8%  |  |
| <b>Restructuring costs</b>                                  |              |              |              |              |              |              |              |              |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |         |  |
| Restructuring costs   | 2.2          | 6.9          | 9.1          | 9.9          | 18.9         | 41.0         | 50.9         | 60.0         | 4.1          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | 88.8%   |  |
| <b>Total</b>  | <b>2.2</b>   | <b>6.9</b>   | <b>9.1</b>   | <b>9.9</b>   | <b>18.9</b>  | <b>41.0</b>  | <b>50.9</b>  | <b>60.0</b>  | <b>4.1</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | 88.8%   |  |
| <b>Integration costs/IT costs</b>                           |              |              |              |              |              |              |              |              |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |         |  |
| Integration Cost  | 1.1          | 1.0          | 2.1          | 1.2          | 3.3          | 0.5          | 1.6          | 3.8          | 1.1          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | 1.2%    |  |
| ERP/HR systems  | 1.7          | 3.9          | 5.6          | 7.4          | 13.0         | 7.7          | 15.1         | 20.7         | 5.1          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | 203.6%  |  |
| <b>Total</b>  | <b>2.8</b>   | <b>4.9</b>   | <b>7.7</b>   | <b>8.6</b>   | <b>16.3</b>  | <b>8.2</b>   | <b>16.8</b>  | <b>24.5</b>  | <b>6.2</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | 121.9%  |  |
| <b>Gain (-)/ losses (+) on the divestment of businesses</b> |              |              |              |              |              |              |              |              |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |         |  |
| Costs related to former business activities                 | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | n.m.    |  |
| <b>Total</b>  | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | n.m.    |  |
| <b>Other one-time costs</b>                                 |              |              |              |              |              |              |              |              |              |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |         |  |
| Others  | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          | 0.0          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | n.m.    |  |
| <b>Total</b>  | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   | <b>0.0</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | n.m.    |  |
| <b>Total adjustments</b>                                    | <b>9.1</b>   | <b>16.9</b>  | <b>26.0</b>  | <b>22.1</b>  | <b>48.1</b>  | <b>49.2</b>  | <b>71.3</b>  | <b>97.3</b>  | <b>11.7</b>  |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | 28.3%   |  |
| <b>EBITDA pre</b>   | <b>237.3</b> | <b>261.7</b> | <b>499.1</b> | <b>207.9</b> | <b>707.0</b> | <b>206.0</b> | <b>413.9</b> | <b>913.0</b> | <b>236.6</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    | -0.3%   |  |

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

\*\* Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Corporate and Other

€ million

|   | 2023          |               |               |               |               |               |               |               | 2024          |            |            |            |            |            |            |            | Change YoY |    |    |    |    |    |    |    |      |         |        |
|---|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|------------|------------|------------|------------|------------|------------|------------|------------|----|----|----|----|----|----|----|------|---------|--------|
|   | Q1            | Q2            | H1            | Q3            | 9M            | Q4            | H2            | FY            | Q1            | Q2         | H1         | Q3         | 9M         | Q4         | H2         | FY         | Q1         | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |      |         |        |
| <b>Net sales</b>                                | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b> | <b>0.0</b> | <b>0.0</b> | <b>0.0</b> | <b>0.0</b> | <b>0.0</b> | <b>0.0</b> |            |    |    |    |    |    |    |    | n.m. |         |        |
| Cost of sales                                   | -0.9          | -2.6          | -3.5          | 1.6           | -1.9          | -1.4          | 0.3           | -3.2          | 0.3           |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | n.m.    |        |
| thereof amortization of intangible assets       | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | n.m.    |        |
| Gross profit                                    | -0.9          | -2.6          | -3.5          | 1.6           | -1.9          | -1.4          | 0.3           | -3.2          | 0.3           |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | n.m.    |        |
| SG&A  | -217.8        | -183.9        | -401.7        | -95.4         | -497.1        | -118.3        | -213.6        | -615.3        | -145.0        |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -33.4%  |        |
| Marketing and selling expenses                  | -2.8          | -3.1          | -5.9          | 0.5           | -5.4          | -1.9          | -1.4          | -7.3          | -0.5          |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -81.0%  |        |
| thereof amortization of intangible assets (M&S) | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -1.2%   |        |
| Administration expenses                         | -144.4        | -127.9        | -272.3        | -90.5         | -362.8        | -143.4        | -233.9        | -506.2        | -107.4        |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -25.6%  |        |
| Impairment losses and reversals (IFRS 9)        | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | -7.6          | -7.6          | -7.6          | 0.0           |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -80.5%  |        |
| Other operating expenses/income                 | -70.6         | -52.9         | -123.5        | -5.4          | -128.9        | 34.6          | 29.2          | -94.3         | -37.2         |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -47.4%  |        |
| Impairments**                                   | 0.0           | 0.0           | 0.0           | -0.1          | -0.1          | -1.2          | -1.3          | -1.3          | 0.0           |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | n.m.    |        |
| Research and development costs                  | -24.1         | -25.3         | -49.4         | -24.7         | -74.0         | -20.4         | -45.1         | -94.4         | -14.6         |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -39.3%  |        |
| thereof amortization of intangible assets (R&D) | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | n.m.    |        |
| <b>EBIT</b>                                     | <b>-242.8</b> | <b>-211.7</b> | <b>-454.5</b> | <b>-118.4</b> | <b>-572.9</b> | <b>-140.0</b> | <b>-258.5</b> | <b>-713.0</b> | <b>-159.3</b> |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -34.4%  |        |
| Depreciation and amortization                   | 28.4          | 28.2          | 56.6          | 26.9          | 83.5          | 26.7          | 53.6          | 110.2         | 28.1          |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -1.2%   |        |
| <b>EBITDA</b>                                   | <b>-214.4</b> | <b>-183.5</b> | <b>-397.9</b> | <b>-91.5</b>  | <b>-489.4</b> | <b>-113.4</b> | <b>-204.9</b> | <b>-602.8</b> | <b>-131.3</b> |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -38.8%  |        |
| <b>EBITDA pre</b>                               | <b>-140.5</b> | <b>-123.9</b> | <b>-264.5</b> | <b>-62.7</b>  | <b>-327.2</b> | <b>-69.5</b>  | <b>-132.3</b> | <b>-396.7</b> | <b>-101.9</b> |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -27.5%  |        |
| <b>Reconciliation to EBITDA pre</b>             |               |               |               |               |               |               |               |               |               |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      |         |        |
| EBITDA  | -214.4        | -183.5        | -397.9        | -91.5         | -489.4        | -113.4        | -204.9        | -602.8        | -131.3        |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      |         | -38.8% |
| <b>Adjustments</b>                              |               |               |               |               |               |               |               |               |               |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      |         |        |
| thereof: Cost of Sales                          | 0.2           | 0.4           | 0.6           | 0.0           | 0.7           | -0.1          | 0.0           | 0.6           | 0.0           |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -100.0% |        |
| thereof: Marketing and selling expenses         | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | n.m.    |        |
| thereof: Administration expenses                | 54.6          | 22.8          | 77.5          | 12.2          | 89.6          | 54.5          | 66.7          | 144.2         | 20.0          |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -63.4%  |        |
| thereof: Other operating expenses/income        | 19.0          | 35.0          | 54.0          | 16.6          | 70.6          | -10.5         | 6.1           | 60.1          | 9.6           |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -49.8%  |        |
| thereof: Research and development               | 0.0           | 1.3           | 1.3           | 0.0           | 1.3           | -0.2          | -0.1          | 1.2           | -0.2          |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | n.m.    |        |
| <b>Total</b>                                    | <b>73.9</b>   | <b>59.6</b>   | <b>133.5</b>  | <b>28.8</b>   | <b>162.2</b>  | <b>43.9</b>   | <b>72.6</b>   | <b>206.1</b>  | <b>29.4</b>   |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -60.3%  |        |
| <b>EBITDA pre</b>                               | <b>-140.5</b> | <b>-123.9</b> | <b>-264.5</b> | <b>-62.7</b>  | <b>-327.2</b> | <b>-69.5</b>  | <b>-132.3</b> | <b>-396.7</b> | <b>-101.9</b> |            |            |            |            |            |            |            |            |    |    |    |    |    |    |    |      | -27.5%  |        |

Due to rounding the sum of individual values may not add up to totals presented.

\*\* Only reflects impairments classified as adjustments.

**Detailed reconciliation - Corporate and Others**

| € million   | 2023          |               |               |               |               |               |               |               | 2024          |    |    |    |    |    |    |    | Change YoY |    |    |    |    |    |    |    |
|---|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|----|----|----|----|----|----|----|------------|----|----|----|----|----|----|----|
|   | Q1            | Q2            | H1            | Q3            | 9M            | Q4            | H2            | FY            | Q1            | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1         | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| <b>EBIT</b>   | <b>-242.8</b> | <b>-211.7</b> | <b>-454.5</b> | <b>-118.4</b> | <b>-572.9</b> | <b>-140.0</b> | <b>-258.5</b> | <b>-713.0</b> | <b>-159.3</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| Regular depreciation and amortization*                      | 28.4          | 28.2          | 56.6          | 26.8          | 83.4          | 25.4          | 52.2          | 108.8         | 28.1          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| Impairments not adjusted                                    | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| Amortization of purchased intangible assets                 | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           | 0.0           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| Impairments (net)**   | 0.0           | 0.0           | 0.0           | 0.1           | 0.1           | 1.2           | 1.3           | 1.3           | 0.0           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>Total depreciation and amortization</b>                  | <b>28.4</b>   | <b>28.2</b>   | <b>56.6</b>   | <b>26.9</b>   | <b>83.5</b>   | <b>26.7</b>   | <b>53.6</b>   | <b>110.2</b>  | <b>28.1</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>EBITDA</b>   | <b>-214.4</b> | <b>-183.5</b> | <b>-397.9</b> | <b>-91.5</b>  | <b>-489.4</b> | <b>-113.4</b> | <b>-204.9</b> | <b>-602.8</b> | <b>-131.3</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>Adjustments</b>  |               |               |               |               |               |               |               |               |               |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>Acquisition costs</b>                                    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    | <b>0.0</b>    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>Restructuring costs</b>                                  |               |               |               |               |               |               |               |               |               |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| Restructuring costs   | 49.0          | 18.5          | 67.6          | 7.9           | 75.4          | 52.0          | 59.8          | 127.4         | 17.2          |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>Total</b>  | <b>49.0</b>   | <b>18.5</b>   | <b>67.6</b>   | <b>7.9</b>    | <b>75.4</b>   | <b>52.0</b>   | <b>59.8</b>   | <b>127.4</b>  | <b>17.2</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>IT project costs</b>                                     |               |               |               |               |               |               |               |               |               |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| Integration Cost  | 0.0           | 0.1           | 0.1           | 0.1           | 0.2           | 0.1           | 0.2           | 0.3           | 0.1           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| ERP/HR systems  | 5.6           | 6.8           | 12.4          | 4.9           | 17.3          | 3.6           | 8.5           | 20.9          | 2.7           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>Total</b>  | <b>5.6</b>    | <b>6.9</b>    | <b>12.5</b>   | <b>5.0</b>    | <b>17.5</b>   | <b>3.7</b>    | <b>8.7</b>    | <b>21.2</b>   | <b>2.8</b>    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>Gain (-)/ losses (+) on the divestment of businesses</b> |               |               |               |               |               |               |               |               |               |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| Costs related to former business activities                 | 0.0           | 21.0          | 21.0          | -3.0          | 18.0          | -16.6         | -19.6         | 1.4           | 0.0           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>Total</b>  | <b>0.0</b>    | <b>21.0</b>   | <b>21.0</b>   | <b>-3.0</b>   | <b>18.0</b>   | <b>-16.6</b>  | <b>-19.6</b>  | <b>1.4</b>    | <b>0.0</b>    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>Other one-time costs</b>                                 |               |               |               |               |               |               |               |               |               |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| Others  | 19.2          | 13.2          | 32.4          | 18.9          | 51.3          | 4.8           | 23.7          | 56.1          | 9.4           |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>Total</b>  | <b>19.2</b>   | <b>13.2</b>   | <b>32.4</b>   | <b>18.9</b>   | <b>51.3</b>   | <b>4.8</b>    | <b>23.7</b>   | <b>56.1</b>   | <b>9.4</b>    |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>Total adjustments</b>                                    | <b>73.9</b>   | <b>59.6</b>   | <b>133.5</b>  | <b>28.8</b>   | <b>162.2</b>  | <b>43.9</b>   | <b>72.6</b>   | <b>206.1</b>  | <b>29.4</b>   |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |
| <b>EBITDA pre</b>   | <b>-140.5</b> | <b>-123.9</b> | <b>-264.5</b> | <b>-62.7</b>  | <b>-327.2</b> | <b>-69.5</b>  | <b>-132.3</b> | <b>-396.7</b> | <b>-101.9</b> |    |    |    |    |    |    |    |            |    |    |    |    |    |    |    |

Due to rounding the sum of individual values may not add up to totals presented.

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments.

\*\* Only reflects impairments classified as adjustments.



**Cash Flow Statement Merck KGaA, Darmstadt, Germany**

| Group   | 2023            |               |                 |                |                 |                |                 |                 | 2024           |    |    |    |    |    |    |    | Change YoY    |    |    |    |    |    |    |    |
|---|-----------------|---------------|-----------------|----------------|-----------------|----------------|-----------------|-----------------|----------------|----|----|----|----|----|----|----|---------------|----|----|----|----|----|----|----|
|   | Q1              | Q2            | H1              | Q3             | 9M              | Q4             | H2              | FY              | Q1             | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1            | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| € million   |                 |               |                 |                |                 |                |                 |                 |                |    |    |    |    |    |    |    |               |    |    |    |    |    |    |    |
| <b>Profit after tax</b>   | 799.7           | 706.1         | 1,505.8         | 740.4          | 2,246.2         | 587.6          | 1,328.0         | 2,833.8         | 699.5          |    |    |    |    |    |    |    | -12.5%        |    |    |    |    |    |    |    |
| Depreciation/amortization/impairment losses/reversals of impairment losses of tangible assets | 455.5           | 482.3         | 937.8           | 435.2          | 1,373.0         | 506.7          | 941.9           | 1,879.7         | 453.5          |    |    |    |    |    |    |    | -0.4%         |    |    |    |    |    |    |    |
| of intangible assets  | 216.6           | 216.7         | 433.3           | 224.3          | 657.6           | 259.6          | 483.9           | 917.2           | 231.5          |    |    |    |    |    |    |    | 6.9%          |    |    |    |    |    |    |    |
| Changes in working capital  | 238.9           | 265.6         | 504.5           | 210.9          | 715.4           | 247.1          | 458.0           | 962.6           | 222.0          |    |    |    |    |    |    |    | -7.1%         |    |    |    |    |    |    |    |
| Changes in inventories  | -223.9          | -52.9         | -276.8          | -35.2          | -312.0          | 171.5          | 136.3           | -140.5          | -177.4         |    |    |    |    |    |    |    | -20.8%        |    |    |    |    |    |    |    |
| Changes in trade accounts receivable  | -322.5          | -106.3        | -428.9          | 91.8           | -337.0          | 248.3          | 340.2           | -88.7           | -40.9          |    |    |    |    |    |    |    | -87.3%        |    |    |    |    |    |    |    |
| Changes in trade accounts payable/ refund liabilities   | -116.5          | 14.7          | -101.8          | 51.8           | -50.0           | 41.6           | 93.3            | -8.5            | -64.0          |    |    |    |    |    |    |    | -45.0%        |    |    |    |    |    |    |    |
| Changes in trade accounts payable/ refund liabilities   | 215.1           | 38.8          | 253.9           | -178.8         | 75.1            | -118.5         | -297.2          | -43.4           | -72.5          |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| Changes in provisions   | -8.0            | 53.3          | 45.3            | 30.2           | 75.5            | 112.9          | 143.1           | 188.4           | 40.0           |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| Changes in other assets and liabilities   | -187.0          | -421.0        | -608.0          | 143.1          | -464.9          | -290.1         | -147.1          | -755.1          | 32.6           |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| Neutralization of gain/loss on disposal of fixed assets and other disposals                   | -0.2            | -145.5        | -145.7          | -7.0           | -152.7          | 2.4            | 4.6             | -150.3          | -7.9           |    |    |    |    |    |    |    | >1,000%       |    |    |    |    |    |    |    |
| Other non-cash income and expenses  | 16.5            | 0.1           | 16.7            | -51.3          | -34.6           | -37.8          | 89.1            | -72.4           | -5.0           |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| <b>Operating Cash Flow</b>  | <b>852.7</b>    | <b>622.4</b>  | <b>1,475.2</b>  | <b>1,255.4</b> | <b>2,730.6</b>  | <b>1,053.1</b> | <b>2,308.5</b>  | <b>3,783.7</b>  | <b>1,035.1</b> |    |    |    |    |    |    |    | <b>21.4%</b>  |    |    |    |    |    |    |    |
| thereof: from discontinued operations   | 0.0             | 0.0           | 0.0             | 0.0            | 0.0             | 0.0            | 0.0             | 0.0             | 0.0            |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| Payments for investments in intangible assets   | -79.0           | -30.9         | -109.9          | -33.7          | -143.5          | -72.6          | -106.3          | -216.2          | -248.0         |    |    |    |    |    |    |    | 214.0%        |    |    |    |    |    |    |    |
| Payments from the disposal of intangible assets   | 4.4             | 125.8         | 130.2           | 4.9            | 135.0           | 0.8            | 5.6             | 135.8           | 5.9            |    |    |    |    |    |    |    | 35.4%         |    |    |    |    |    |    |    |
| Payments for investments in property, plant and equipment                                     | -572.3          | -295.6        | -867.9          | -428.4         | -1,296.3        | -511.0         | -939.4          | -1,807.4        | -522.8         |    |    |    |    |    |    |    | -8.6%         |    |    |    |    |    |    |    |
| Payments from the disposal of property, plant and equipment                                   | 10.1            | 3.3           | 13.4            | 4.2            | 17.6            | 1.1            | 5.4             | 18.7            | 10.7           |    |    |    |    |    |    |    | 5.8%          |    |    |    |    |    |    |    |
| Payments for acquisitions less acquired cash and cash equivalents (net)                       | 0.1             | 0.1           | 0.1             | -9.4           | -9.3            | -2.5           | -11.9           | -11.8           | 0.0            |    |    |    |    |    |    |    | -100.0%       |    |    |    |    |    |    |    |
| Payments from other divestments   | -0.1            | -0.2          | -0.2            | 0.0            | -0.2            | 0.0            | 0.0             | -0.2            | 6.3            |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| Payments for investments in financial assets  | -21.9           | -12.2         | -34.1           | -58.8          | -92.9           | -444.3         | -503.1          | -537.2          | -87.5          |    |    |    |    |    |    |    | 300.0%        |    |    |    |    |    |    |    |
| Proceeds from the disposal of other financial assets  | 224.5           | 42.9          | 267.5           | 167.0          | 434.4           | 75.4           | 242.3           | 509.8           | 346.7          |    |    |    |    |    |    |    | 54.4%         |    |    |    |    |    |    |    |
| Payments for the acquisition of non-financial assets  | -897.0          | -1,107.1      | -2,004.1        | -300.0         | -2,304.2        | -190.0         | -490.1          | -2,494.2        | -200.0         |    |    |    |    |    |    |    | -77.7%        |    |    |    |    |    |    |    |
| Proceeds from the disposal of non-financial assets  | 100.0           | 1,414.1       | 1,514.1         | 303.9          | 1,818.0         | 692.8          | 996.7           | 2,510.8         | 0.0            |    |    |    |    |    |    |    | -100.0%       |    |    |    |    |    |    |    |
| <b>Investing Cash Flow</b>  | <b>-1,231.1</b> | <b>140.2</b>  | <b>-1,091.0</b> | <b>-350.3</b>  | <b>-1,441.3</b> | <b>-450.5</b>  | <b>-800.8</b>   | <b>-1,891.8</b> | <b>-688.7</b>  |    |    |    |    |    |    |    | <b>-44.1%</b> |    |    |    |    |    |    |    |
| thereof: from discontinued operations   | 0.0             | 0.0           | 0.0             | 0.0            | 0.0             | 0.0            | 0.0             | 0.0             | 0.0            |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| Dividend payments to Merck KGaA shareholders  | 0.0             | -284.3        | -284.3          | 0.0            | -284.3          | 0.0            | 0.0             | -284.3          | 0.0            |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| Dividend payments to non-controlling interests  | 0.0             | -10.3         | -10.3           | -0.3           | -10.6           | -1.1           | -1.4            | -11.7           | 0.0            |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| Profit withdrawal by E.Merck KG   | -90.4           | -777.6        | -868.0          | 0.0            | -868.0          | 0.0            | 0.0             | -868.0          | -52.3          |    |    |    |    |    |    |    | -42.1%        |    |    |    |    |    |    |    |
| Changes in financial liabilities to E. Merck KG and E. Merck Beteiligungen KG                 | -0.8            | 697.8         | 697.1           | -100.0         | 597.1           | -320.4         | -420.4          | 276.7           | -26.9          |    |    |    |    |    |    |    | >1,000%       |    |    |    |    |    |    |    |
| Other changes in net equity   | 0.0             | 0.0           | 0.0             | 0.1            | 0.1             | 0.2            | 0.3             | 0.3             | -0.1           |    |    |    |    |    |    |    | >1,000%       |    |    |    |    |    |    |    |
| Changes in current and non-current financial liabilities                                      | 215.6           | -206.0        | 9.7             | -202.2         | -192.5          | -652.7         | -854.9          | -845.3          | -27.6          |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| Other changes from financing activities   | 0.0             | 0.0           | 0.0             | 0.0            | 0.0             | 0.0            | 0.0             | 0.0             | 0.0            |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| <b>Financing Cash Flow</b>  | <b>124.5</b>    | <b>-580.4</b> | <b>-455.9</b>   | <b>-302.4</b>  | <b>-758.3</b>   | <b>-974.0</b>  | <b>-1,276.4</b> | <b>-1,732.3</b> | <b>-106.9</b>  |    |    |    |    |    |    |    | <b>n.m.</b>   |    |    |    |    |    |    |    |
| thereof: from discontinued operations   | 0.0             | 0.0           | 0.0             | 0.0            | 0.0             | 0.0            | 0.0             | 0.0             | 0.0            |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |
| <b>Changes in cash and cash equivalents</b>   | <b>-254.0</b>   | <b>182.2</b>  | <b>-71.7</b>    | <b>602.7</b>   | <b>530.9</b>    | <b>-371.3</b>  | <b>231.3</b>    | <b>159.6</b>    | <b>239.5</b>   |    |    |    |    |    |    |    | <b>n.m.</b>   |    |    |    |    |    |    |    |
| Changes in cash and cash equivalents due to currency translation                              | -15.7           | -5.3          | -21.1           | 1.7            | -19.3           | -12.1          | -10.4           | -31.4           | -2.0           |    |    |    |    |    |    |    | -87.5%        |    |    |    |    |    |    |    |
| Cash and cash equivalents as of January 1st   | 1,853.8         | 0.0           | 1,853.8         | 0.0            | 1,853.8         | 0.0            | 0.0             | 1,853.8         | 1,982.0        |    |    |    |    |    |    |    | 6.9%          |    |    |    |    |    |    |    |
| <b>Cash and cash equivalents</b>  | <b>1,584.1</b>  | <b>176.9</b>  | <b>1,761.0</b>  | <b>604.4</b>   | <b>2,365.4</b>  | <b>-363.4</b>  | <b>221.0</b>    | <b>1,982.0</b>  | <b>2,219.6</b> |    |    |    |    |    |    |    | <b>40.1%</b>  |    |    |    |    |    |    |    |
| Changes in cash and cash equivalents due to change in scope of consolidation                  | 0.0             | 0.0           | 0.0             | 0.0            | 0.0             | 0.0            | 0.0             | 0.0             | 0.0            |    |    |    |    |    |    |    | n.m.          |    |    |    |    |    |    |    |

Due to rounding the sum of individual values may not add up to totals presented.

**Balance Sheet Merck KGaA, Darmstadt, Germany**
**Group**

€ million

|   | 2023            |                 |                 |                  | 2024            |        |        |        | Shares of Totals |        |        |        | Shares of Totals |        |        |        |
|---|-----------------|-----------------|-----------------|------------------|-----------------|--------|--------|--------|------------------|--------|--------|--------|------------------|--------|--------|--------|
|   | 31.mar          | 30.cze          | 30.wrz          | 31.Dez           | 31.mar          | 30.cze | 30.wrz | 31.gru | 31.mar           | 30.cze | 30.wrz | 31.Dez | 31.mar           | 30.cze | 30.wrz | 31.gru |
| <b>Non-current assets</b>   | <b>35,686.3</b> | <b>35,763.3</b> | <b>36,339.9</b> | <b>36,102.3</b>  | <b>36,680.9</b> |        |        |        | 73.4%            | 73.3%  | 72.8%  | 74.4%  | 74.1%            |        |        |        |
| Goodwill  | 18,077.4        | 18,102.2        | 18,466.3        | 17,844.9         | 18,180.8        |        |        |        | 37.2%            | 37.1%  | 37.0%  | 36.8%  | 36.7%            |        |        |        |
| Other intangible assets   | 6,953.8         | 6,765.2         | 6,716.5         | 6,551.3          | 6,480.6         |        |        |        | 14.3%            | 13.9%  | 13.5%  | 13.5%  | 13.1%            |        |        |        |
| Property, plant and equipment                                       | 8,217.9         | 8,393.4         | 8,719.2         | 9,055.9          | 9,214.4         |        |        |        | 16.9%            | 17.2%  | 17.5%  | 18.7%  | 18.6%            |        |        |        |
| Investments accounted for using the equity method                   | 2.9             | 2.9             | 3.0             | 2.9              | 2.9             |        |        |        | 0.0%             | 0.0%   | 0.0%   | 0.0%   | 0.0%             |        |        |        |
| Other non-current receivables                                       | 23.9            | 23.2            | 24.4            | 27.5             | 26.9            |        |        |        | 0.0%             | 0.0%   | 0.0%   | 0.1%   | 0.1%             |        |        |        |
| Other non-current financial assets                                  | 958.9           | 1,040.9         | 989.8           | 980.8            | 1,067.7         |        |        |        | 2.0%             | 2.1%   | 2.0%   | 2.0%   | 2.2%             |        |        |        |
| Other non-current non-financial assets                              | 99.6            | 88.1            | 96.3            | 115.3            | 138.1           |        |        |        | 0.2%             | 0.2%   | 0.2%   | 0.2%   | 0.3%             |        |        |        |
| Non-current income tax receivables                                  | 9.3             | 9.2             | 9.3             | 9.2              | 9.1             |        |        |        | 0.0%             | 0.0%   | 0.0%   | 0.0%   | 0.0%             |        |        |        |
| Deferred tax assets   | 1,342.5         | 1,338.2         | 1,315.1         | 1,514.3          | 1,560.4         |        |        |        | 2.8%             | 2.7%   | 2.6%   | 3.1%   | 3.2%             |        |        |        |
| <b>Current assets</b>   | <b>12,950.7</b> | <b>13,018.7</b> | <b>13,566.4</b> | <b>12,393.2</b>  | <b>12,823.5</b> |        |        |        | 26.6%            | 26.7%  | 27.2%  | 25.6%  | 25.9%            |        |        |        |
| Inventories   | 4,889.6         | 4,995.8         | 4,971.1         | 4,636.9          | 4,716.4         |        |        |        | 10.1%            | 10.2%  | 10.0%  | 9.6%   | 9.5%             |        |        |        |
| Trade and other current receivables                                 | 4,269.8         | 4,209.8         | 4,195.1         | 4,003.9          | 4,147.1         |        |        |        | 8.8%             | 8.6%   | 8.4%   | 8.3%   | 8.4%             |        |        |        |
| Contract assets   | 132.6           | 126.5           | 122.1           | 103.7            | 99.1            |        |        |        | 0.3%             | 0.3%   | 0.2%   | 0.2%   | 0.2%             |        |        |        |
| Other current financial assets                                      | 136.8           | 166.3           | 218.3           | 499.1            | 264.1           |        |        |        | 0.3%             | 0.3%   | 0.4%   | 1.0%   | 0.5%             |        |        |        |
| Other current non-financial assets                                  | 1,515.8         | 1,250.0         | 1,140.2         | 632.5            | 942.4           |        |        |        | 3.1%             | 2.6%   | 2.3%   | 1.3%   | 1.9%             |        |        |        |
| Current income tax receivables                                      | 421.9           | 509.2           | 554.2           | 472.8            | 434.8           |        |        |        | 0.9%             | 1.0%   | 1.1%   | 1.0%   | 0.9%             |        |        |        |
| Cash and cash equivalents   | 1,584.1         | 1,761.0         | 2,365.4         | 1,982.0          | 2,219.6         |        |        |        | 3.3%             | 3.6%   | 4.7%   | 4.1%   | 4.5%             |        |        |        |
| Assets held for sale  | 0.0             | 0.0             | 0.0             | 62.3             | 0.0             |        |        |        | 0.0%             | 0.0%   | 0.0%   | 0.1%   | 0.0%             |        |        |        |
| <b>Total assets</b>   | <b>48,637.0</b> | <b>48,781.9</b> | <b>49,906.2</b> | <b>48,495.4</b>  | <b>49,504.4</b> |        |        |        | 100.0%           | 100.0% | 100.0% | 100.0% | 100.0%           |        |        |        |
| <b>Total equity</b>   | <b>26,230.0</b> | <b>26,771.9</b> | <b>28,294.5</b> | <b>26,754.31</b> | <b>28,074.2</b> |        |        |        | 53.9%            | 54.9%  | 56.7%  | 55.2%  | 56.7%            |        |        |        |
| Equity capital  | 565.2           | 565.2           | 565.2           | 565.2            | 565.2           |        |        |        | 1.2%             | 1.2%   | 1.1%   | 1.2%   | 1.1%             |        |        |        |
| Capital reserves  | 3,813.7         | 3,813.7         | 3,813.7         | 3,813.73         | 3,813.7         |        |        |        | 7.8%             | 7.8%   | 7.6%   | 7.9%   | 7.7%             |        |        |        |
| Retained earnings   | 19,250.0        | 19,760.5        | 20,710.7        | 20,228.20        | 21,031.1        |        |        |        | 39.6%            | 40.5%  | 41.5%  | 41.7%  | 42.5%            |        |        |        |
| Gain/losses recognized in equity                                    | 2,520.3         | 2,561.2         | 3,132.2         | 2,072.6          | 2,585.9         |        |        |        | 5.2%             | 5.3%   | 6.3%   | 4.3%   | 5.2%             |        |        |        |
| Non-controlling interest  | 80.7            | 71.3            | 72.7            | 74.53            | 78.2            |        |        |        | 0.2%             | 0.1%   | 0.1%   | 0.2%   | 0.2%             |        |        |        |
| <b>Non-current liabilities</b>                                      | <b>12,850.8</b> | <b>13,163.9</b> | <b>12,926.3</b> | <b>13,041.7</b>  | <b>11,491.1</b> |        |        |        | 26.4%            | 27.0%  | 25.9%  | 26.9%  | 23.2%            |        |        |        |
| Non-current provisions for employee benefits                        | 1,965.3         | 1,994.5         | 1,773.6         | 2,192.0          | 2,132.9         |        |        |        | 4.0%             | 4.1%   | 3.6%   | 4.5%   | 4.3%             |        |        |        |
| Other non-current provisions  | 307.0           | 294.1           | 276.0           | 277.4            | 262.7           |        |        |        | 0.6%             | 0.6%   | 0.6%   | 0.6%   | 0.5%             |        |        |        |
| Non-current financial debt  | 9,159.3         | 9,495.4         | 9,540.5         | 9,239.5          | 7,822.5         |        |        |        | 18.8%            | 19.5%  | 19.1%  | 19.1%  | 15.8%            |        |        |        |
| Other non-current financial liabilities                             | 142.4           | 141.3           | 142.8           | 147.1            | 150.5           |        |        |        | 0.3%             | 0.3%   | 0.3%   | 0.3%   | 0.3%             |        |        |        |
| Other non-current non-financial liabilities                         | 19.3            | 19.0            | 18.2            | 16.5             | 16.3            |        |        |        | 0.0%             | 0.0%   | 0.0%   | 0.0%   | 0.0%             |        |        |        |
| Non-current income tax liabilities                                  | 38.0            | 37.5            | 41.0            | 39.5             | 39.4            |        |        |        | 0.1%             | 0.1%   | 0.1%   | 0.1%   | 0.1%             |        |        |        |
| Deferred tax liabilities  | 1,219.4         | 1,182.1         | 1,134.3         | 1,129.6          | 1,066.7         |        |        |        | 2.5%             | 2.4%   | 2.3%   | 2.3%   | 2.2%             |        |        |        |
| <b>Current liabilities</b>  | <b>9,556.2</b>  | <b>8,846.1</b>  | <b>8,685.4</b>  | <b>8,699.4</b>   | <b>9,939.1</b>  |        |        |        | 19.6%            | 18.1%  | 17.4%  | 17.9%  | 20.1%            |        |        |        |
| Current provisions for employee benefits                            | 131.6           | 105.9           | 124.4           | 82.9             | 81.3            |        |        |        | 0.3%             | 0.2%   | 0.2%   | 0.2%   | 0.2%             |        |        |        |
| Other current provisions  | 378.8           | 448.1           | 469.0           | 575.0            | 594.0           |        |        |        | 0.8%             | 0.9%   | 0.9%   | 1.2%   | 1.2%             |        |        |        |
| Current financial debt  | 1,484.9         | 1,690.1         | 1,415.7         | 701.5            | 2,130.5         |        |        |        | 3.1%             | 3.5%   | 2.8%   | 1.4%   | 4.3%             |        |        |        |
| Other current financial liabilities                                 | 1,017.3         | 259.1           | 241.8           | 1,005.1          | 994.4           |        |        |        | 2.1%             | 0.5%   | 0.5%   | 2.1%   | 2.0%             |        |        |        |
| Trade and other current payables                                    | 2,326.1         | 2,402.7         | 2,243.8         | 2,545.4          | 2,086.0         |        |        |        | 4.8%             | 4.9%   | 4.5%   | 5.2%   | 4.2%             |        |        |        |
| Refund liabilities  | 947.1           | 963.1           | 990.0           | 876.8            | 880.9           |        |        |        | 1.9%             | 2.0%   | 2.0%   | 1.8%   | 1.8%             |        |        |        |
| Current income tax liabilities                                      | 1,461.4         | 1,487.8         | 1,580.7         | 1,433.4          | 1,564.9         |        |        |        | 3.0%             | 3.0%   | 3.2%   | 3.0%   | 3.2%             |        |        |        |
| Other current non-financial liabilities                             | 1,809.1         | 1,489.4         | 1,620.1         | 1,479.4          | 1,607.1         |        |        |        | 3.7%             | 3.1%   | 3.2%   | 3.1%   | 3.2%             |        |        |        |
| Liabilities included in disposal groups classified as held for sale | 0.0             | 0.0             | 0.0             | 0.0              | 0.0             |        |        |        | 0.0%             | 0.0%   | 0.0%   | 0.0%   | 0.0%             |        |        |        |
| <b>Total liabilities and stockholders' equity</b>                   | <b>48,637.0</b> | <b>48,781.9</b> | <b>49,906.2</b> | <b>48,495.4</b>  | <b>49,504.4</b> |        |        |        | 100.0%           | 100.0% | 100.0% | 100.0% | 100.0%           |        |        |        |

Due to rounding the sum of individual values may not add up to totals presented.

<sup>1</sup> Figures are year-to-date figures from January 1st until stated end date.